Document:

EX-4.1

 Exhibit 4.1 

MEDTRONIC GLOBAL HOLDINGS S.C.A. 

as Issuer, 
 MEDTRONIC
PUBLIC LIMITED COMPANY 
 and MEDTRONIC, INC. 

as Guarantors, 

COMPUTERSHARE TRUST COMPANY, N.A. as successor to 

WELLS FARGO BANK, NATIONAL ASSOCIATION, 

as Trustee, 
 and

 ELAVON FINANCIAL SERVICES DAC, 

as Paying Agent 
 FIFTH
SUPPLEMENTAL INDENTURE 
 DATED AS OF SEPTEMBER 21, 2022 

TO INDENTURE 
 DATED AS
OF MARCH 28, 2017 
 Relating to 

€500,000,000 2.625% Senior Notes due 2025 

€1,000,000,000 3.000% Senior Notes due 2028 

€1,000,000,000 3.125% Senior Notes due 2031 

€1,000,000,000 3.375% Senior Notes due 2034 

 FIFTH SUPPLEMENTAL INDENTURE 

FIFTH SUPPLEMENTAL INDENTURE, dated as of September 21, 2022 (the “Supplemental Indenture”), to the Base Indenture
(defined below) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a corporate partnership limited by shares (société en commandite par actions) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its
registered office at Espace Monterey, 40, Avenue Monterey, Ground Floor, L-2163 Luxembourg, Grand Duchy of Luxembourg and registered with the Luxembourg Trade and Companies Register under number B191129 (the
“Company”), MEDTRONIC PUBLIC LIMITED COMPANY, a public limited company incorporated under the laws of Ireland (“Parent”), MEDTRONIC, INC., a Minnesota corporation (“Medtronic, Inc.” and, together
with Parent, the “Guarantors”), Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, a national banking association duly organized under the laws of the United States, as Trustee (herein called
the “Trustee”) and ELAVON FINANCIAL SERVICES DAC, as paying agent. 
 RECITALS 

WHEREAS, the Company and the Guarantors executed and delivered to the Trustee the Indenture, dated as of March 28, 2017 (the
“Base Indenture” and, together with this Supplemental Indenture, the “Indenture”), providing for the issuance from time to time of the Company’s Securities; 

WHEREAS, pursuant to the terms of the Base Indenture, the Company desires to provide for the establishment of four new series of its
Securities to be known as its 2.625% Senior Notes due 2025 (the “2025 Notes”), 3.000% Senior Notes due 2028 (the “2028 Notes”), 3.125% Senior Notes due 2031 (the “2031 Notes”) and 3.375% Senior
Notes due 2034 (the “2034 Notes” and, together with the 2025 Notes, the 2028 Notes and the 2031 Notes, the “Notes”), to be fully and unconditionally guaranteed by the Guarantors (the
“Guarantees”), the form and substance of such Notes and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Supplemental Indenture; 

WHEREAS, the Company has requested that the Trustee and the Paying Agent execute and deliver this Supplemental Indenture, and all requirements
necessary to make this Supplemental Indenture a valid instrument in accordance with its terms, to make the Notes, when executed by the Company and authenticated and delivered by the Trustee, the valid and legally binding obligations of the Company,
to make the Guarantees, when executed by the Guarantors, the valid and legally binding obligations of the Guarantors, and all acts and things necessary have been done and performed to make this Supplemental Indenture enforceable in accordance with
its terms, and the execution and delivery of this Supplemental Indenture have been duly authorized in all respects. 

 WITNESSETH: 

NOW, THEREFORE, for and in consideration of the premises contained herein, each party agrees for the benefit of each other party and for the
equal and ratable benefit of the Holders of the Notes, as follows: 
 ARTICLE 1 

DEFINITIONS 
 Section 1.01.
Capitalized terms used but not defined in this Supplemental Indenture shall have the meanings ascribed to them in the Base Indenture. 

Section 1.02. References in this Supplemental Indenture to article and section numbers shall be deemed to be references to article and
section numbers of this Supplemental Indenture unless otherwise specified. 
 Section 1.03. For purposes of this Supplemental
Indenture, the following terms have the meanings ascribed to them as follows: 
 “2025 Notes” has the meaning provided in
the recitals. 
 “2028 Notes” has the meaning provided in the recitals. 

“2031 Notes” has the meaning provided in the recitals. 

“2034 Notes” has the meaning provided in the recitals. 

“Base Indenture” has the meaning provided in the recitals. 

“Business Day” means any day, other than a Saturday or Sunday, (1) which is not a day on which banking institutions in
The City of New York or London are authorized or required by law, regulation or executive order to close and (2) on which the Trans-European Automated Real-Time Gross Settlement Express Transfer system, or any successor thereto, is open. 

“Clearstream” means Clearstream Banking, société anonyme. 

“Company” has the meaning provided in the preamble. 

“Euro” and “€” means the single currency introduced at the third stage of the European Economic and
Monetary Union pursuant to the Treaty establishing the European Community, as amended. 
 “Euroclear” means Euroclear Bank
SA/NV, as operator of the Euroclear System. 
 “Guarantor” has the meaning provided in the preamble. 

“Indenture” has the meaning provided in the recitals. 

  
 3 

 “Interest Payment Date” has the meaning provided in Section 2.04. 

“Medtronic, Inc.” has the meaning provided in the preamble. 

“Notes” has the meaning provided in the recitals. 

“Parent” has the meaning provided in the preamble. 

“Paying Agent” has the meaning provided in Section 2.03(d). 

“Supplemental Indenture” has the meaning provided in the preamble. 

“Trustee” has the meaning provided in the preamble. 

“U.S. Dollar” means the lawful currency of the United States of America. 

ARTICLE 2 
 GENERAL TERMS AND
CONDITIONS OF THE NOTES 
 Section 2.01. Designation and Principal Amount. The 2025 Notes, the 2028 Notes, the 2031 Notes and
the 2034 Notes are hereby authorized, each unlimited in aggregate principal amount. The 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes issued on the date hereof pursuant to the terms of this Indenture shall be in an aggregate
principal amount of €500,000,000, €1,000,000,000, €1,000,000,000 and €1,000,000,000, respectively, which amounts shall be set forth in the written order of the Company for the authentication and delivery of the Notes pursuant to
Section 3.03 of the Base Indenture. In addition, the Company may, from time to time, without notice to or the consent of the Holders of the Notes, create and issue additional Notes of any series ranking equally and ratably with the Notes of
such series issued on the date hereof in all respects (or in all respects except for the payment of interest accruing prior to the issue date of such additional Notes or except for the first payment of interest following the issue date of such
additional Notes), so that such additional Notes shall be consolidated and form a single series with such series of Notes issued on the date hereof and shall have the same terms as to status, redemption or otherwise as such series of Notes issued on
the date hereof; provided, that if any such additional Notes are not fungible with the Notes of such series initially issued hereunder for U.S. federal income tax purposes, such additional Notes shall have a separate CUSIP/ISIN number. 

Section 2.02. Maturity. The principal amount of the 2025 Notes shall be payable on October 15, 2025, the principal amount of
the 2028 Notes shall be payable on October 15, 2028, the principal amount of the 2031 Notes shall be payable on October 15, 2031 and the principal amount of the 2034 Notes shall be payable on October 15, 2034. 

Section 2.03. Form and Payment. (a) The Notes shall be issued as global notes, only in fully registered book-entry form,
without coupons, in minimum denominations of €100,000 and integral multiples of €1,000 in excess thereof. 

  
 4 

 (b) Payments of principal, premium, if any, and/or interest, if any, on the global notes
representing the Notes shall be made to the Paying Agent (defined below) which in turn shall make payment to Euroclear and Clearstream as the Depositary with respect to the Notes of such series or its nominee. 

(c) The global notes representing the Notes shall be deposited with, or on behalf of, the Depositary, and shall be registered, at the request
of the Depositary, in the name of the nominee of the Depositary, for Euroclear and Clearstream. 
 (d) The Company initially appoints U.S.
Bank National Association as Security Registrar with respect to the Notes pursuant to Section 3.05 of the Base Indenture until such time as the Security Registrar has resigned or a successor has been appointed. Elavon Financial Services DAC
shall initially act as paying agent (the “Paying Agent”) for the Notes. The Company may appoint and change the Paying Agent without prior notice to the Holders. 

Section 2.04. Interest. Interest on the Notes shall accrue at the rate of 2.625% per annum for the 2025 Notes, 3.000% per annum
for the 2028 Notes, 3.125% per annum for the 2031 Notes and 3.375% per annum for the 2034 Notes. Interest on the Notes shall be payable annually in arrears on October 15, commencing on October 15, 2023 (each such date, an “Interest
Payment Date”), to the Holders in whose names the respective Notes are registered at the close of business on the Business Day (which shall for purposes of this Section 2.04 include only days on which Clearstream and Euroclear are open
for business) immediately preceding the applicable Interest Payment Date. Interest on the Notes shall be computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and
including the last date on which interest was paid on the notes (or September 21, 2022, if no interest has been paid on the applicable series of Notes), to, but excluding, the next scheduled Interest Payment Date. If any Interest Payment Date
(other than a maturity date or redemption date) would otherwise be a day that is not a Business Day, such Interest Payment Date will be postponed to the next date that is a Business Day and no interest will accrue on the amounts payable from and
after such Interest Payment Date to the next Business Day. If the maturity date or redemption date of any series of Notes would fall on a day that is not a Business Day, then the related payment of principal, premium, if any, and interest, if any,
shall be made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and no interest shall accrue on the amounts so payable for the period from and after such date to the next Business Day.

 Section 2.05. Issuance in Euro. (a) Principal, including any payments made upon any redemption or repurchase of the
Notes, premium, if any, and interest payments, if any, in respect of the Notes will be payable in Euros. 
 (b) Distributions of principal,
premium, if any, and interest, if any, with respect to any Global Security will be credited in euros to the extent received by Euroclear or Clearstream from the Paying Agent to the cash accounts of Euroclear or Clearstream customers in accordance
with the relevant system’s rules and procedures. 

  
 5 

 (c) If on or after the date hereof, the Euro is unavailable to the Company or, in the case
of the Guarantees, Parent or Medtronic, Inc., due to the imposition of exchange controls or other circumstances beyond the Company’s, Parent’s or Medtronic, Inc.’s control or if the Euro is no longer being used by the then member
states of the European Economic and Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the Notes
will be made in U.S. Dollars until the Euro is again available to the Company or, in the case of the Guarantees, Parent or Medtronic, Inc., or so used. In such circumstances, the amount payable on any date in Euro will be converted by the Company
into U.S. Dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant Interest Payment Date or, in the event the U.S. Federal Reserve Board has not mandated a rate of
conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date. Any payment in respect of the Notes so made in U.S. Dollars
will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with this Section 2.05. 

Section 2.06. Other Terms. The Notes shall be unsecured senior indebtedness of the Company and shall rank equally and ratably in
right of payment with all of the Company’s other unsecured and unsubordinated indebtedness outstanding from time to time. The Notes shall not be convertible into, or exchangeable for, any other securities of the Company, except that the Notes
shall be exchangeable for other Notes to the extent provided for in the Base Indenture. 
 ARTICLE 3 

REDEMPTION OF THE NOTES 

Section 3.01. Optional Redemption. (a) The Company may redeem any series of the 2025 Notes, the 2028 Notes, the 2031 Notes
and the 2034 Notes, at any time prior to the applicable Par Call Date, at a Redemption Price equal to the greater of: 
 (i)
100% of the principal amount of the Notes to be redeemed, and 
 (ii) the sum, as determined by a Quotation Agent, of the
present values of the Remaining Scheduled Payments of principal and interest on the Notes of such series to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Notes matured on the
applicable Par Call Date), discounted to the Redemption Date on an annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 20 basis points, in the case of the 2025 Notes and 25 basis points, in the case of each of the 2028 Notes, the
2031 Notes and the 2034 Notes; 
 plus, in each case, accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

  
 6 

 (b) At any time on and after the applicable Par Call Date, the Company may redeem each
series of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes at the Company’s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest,
if any, to, but not including, the applicable Redemption Date. 
 (c) Notwithstanding anything to the contrary in the Base Indenture, in the
case of any redemption at the election of the Company, the Company shall, at least 10 days prior to the date on which the Company mails the notice of redemption to each holder (unless a shorter notice shall be satisfactory to the Trustee), notify
the Trustee and the Paying Agent of the applicable Redemption Date, of the principal amount of Notes of such series to be redeemed and, if applicable, of the tenor of the Notes to be redeemed. 

(d) Notwithstanding anything to the contrary in the Base Indenture, (i) notice of redemption shall be delivered not less than 10 nor more
than 60 days prior to the applicable Redemption Date, to each Holder of Notes to be redeemed, at such Holder’s address appearing in the Security Register and (ii) an Officers’ Certificate specifying the actual redemption price shall
be sent to the Trustee no later than two Business Days prior to the Redemption Date. A notice of redemption may, at the discretion of the Company, be subject to one or more conditions precedent, including, but not limited to, completion of an equity
offering, a financing, or other corporate transaction, provided that if such redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in the Company’s discretion, the redemption date may
be postponed until up to 60 days following the notice of redemption, and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the redemption date (including as it may be postponed). 

(e) Notes may be redeemed in part in the minimum authorized denomination or in any integral multiple of such amount. 

(f) For purposes of this Section 3.01, the following definitions are applicable: 

“Comparable Bond Rate” means, for any Redemption Date, the rate per annum equal to the annual equivalent yield to maturity or
interpolated yield to maturity (on a day count basis), computed as of the third Business Day immediately preceding that Redemption Date, of the Comparable Government Issue, assuming a price for the Comparable Government Issue (expressed as a
percentage of its principal amount) equal to the Comparable Price for such Redemption Date. 
 “Comparable Government
Issue” means the euro-denominated security issued by the German federal government selected by a Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the Notes to be redeemed (assuming that such
Notes matured on the applicable Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of
the Notes to be redeemed. 

  
 7 

 “Comparable Price” means, with respect to any Redemption Date, (i) the
average of the Reference Dealer Quotations for such Redemption Date, after excluding the highest and lowest of the Reference Dealer Quotations, (ii) if the Company obtains fewer than four Reference Dealer Quotations, the arithmetic average of
all those Reference Dealer Quotations or (iii) if the Company obtains only one Reference Dealer Quotation, such Reference Dealer Quotation. 

“Par Call Date” means in the case of the 2025 Notes, September 15, 2025; in the case of the 2028 Notes, July 15,
2028; in the case of the 2031 Notes, July 15, 2031; and in the case of the 2034 Notes, July 15, 2034. 
 “Quotation
Agent” means the Reference Dealer appointed by the Company. 
 “Reference Dealer” means (i) each of Barclays
Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe and their respective successors; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and/or a market maker in,
German government bonds (a “Primary Bond Dealer”), the Company shall substitute another Primary Bond Dealer and (ii) any other Primary Bond Dealers selected by the Company. 

“Reference Dealer Quotations” means, with respect to each Reference Dealer and any Redemption Date, the average, as
determined by the Quotation Agent, of the bid and asked prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by such Reference Dealer at 11:00 a.m.,
London time, on the third Business Day preceding such Redemption Date. 
 “Remaining Scheduled Payments” means, with
respect to each of the Notes to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption (assuming that the Notes to be redeemed matured
on the applicable Par Call Date); provided, however, that if such Redemption Date is not an Interest Payment Date with respect to such Note, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of
interest accrued thereon to such Redemption Date. 
 Section 3.02. Article 15 of the Base Indenture shall apply to each series of
Notes; provided that the first sentence of Section 15.01 shall be amended by inserting “Ireland” immediately after “Luxembourg,” therein. 

ARTICLE 4 
 MISCELLANEOUS 

Section 4.01. Covenant Defeasance. Article 13 of the Base Indenture shall be applicable to the Notes. 

  
 8 

 Section 4.02. Form of Notes. (a) The Notes and the Trustee’s
certificates of authentication to be endorsed thereon are to be substantially in the forms of Exhibits A through D attached hereto, which forms are hereby incorporated in and made a part of this Supplemental Indenture. 

(b) The terms and provisions contained in the Notes shall constitute, and are hereby expressly made, a part of this Supplemental Indenture,
and the Company, the Trustee and the Paying Agent, by their execution and delivery of this Supplemental Indenture, expressly agree to such terms and provisions and to be bound thereby. 

Section 4.03. Ratification of Base Indenture. The Base Indenture, as supplemented by this Supplemental Indenture, is in all
respects ratified and confirmed, and this Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent herein and therein provided. 

Section 4.04. Trust Indenture Act Controls. If any provision hereof limits, qualifies or conflicts with the duties imposed by
Section 310 through Section 317 of the Trust Indenture Act of 1939, the imposed duties shall control. 
 Section 4.05.
Listing. Upon listing of the Notes of a series on the New York Stock Exchange, the Company will use commercially reasonable efforts to maintain such listing and satisfy the requirements for such continued listing as long as the Notes of such
series are outstanding. 
 Section 4.06. Conflict with Indenture. To the extent not expressly amended or modified by this
Supplemental Indenture, the Base Indenture shall remain in full force and effect. If any provision of this Supplemental Indenture relating to the Notes is inconsistent with any provision of the Base Indenture, the provision of this Supplemental
Indenture shall control. 
 Section 4.07. Governing Law. THIS SUPPLEMENTAL INDENTURE AND THE NOTES SHALL BE DEEMED TO BE A
CONTRACT UNDER THE LAWS OF THE STATE OF NEW YORK, AND FOR ALL PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF SUCH STATE, EXCEPT AS MAY OTHERWISE BE REQUIRED BY MANDATORY PROVISIONS OF LAW. FOR THE AVOIDANCE OF DOUBT, THE APPLICABILITY OF
ARTICLES 470-3 TO 470-19 OF THE LUXEMBOURG LAW ON COMMERCIAL COMPANIES DATED AUGUST 10, 1915 ON COMMERCIAL COMPANIES, AS AMENDED, SHALL BE EXCLUDED. 

Section 4.08. Service of Process. The Company and each Guarantor appoints Corporation Service Company, with offices at 80 State
Street, Albany, New York 12207-2543, United States, as its agent to receive service of process or other legal summons for purposes of any suit, action or proceeding based on or arising out of or relating to this Supplemental Indenture or any Notes
or Guarantees. 
 Section 4.09. Successors. All agreements of the Company and the Guarantor in the Base Indenture, this
Supplemental Indenture and the Notes shall bind their respective successors. All agreements of the Trustee in the Base Indenture and this Supplemental Indenture shall bind its successors. 

  
 9 

 Section 4.10. Counterparts. This instrument may be executed in any number of
counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be
their original signatures for all purposes. This Supplemental Indenture shall be valid, binding, and enforceable against a party only when executed and delivered by an authorized individual on behalf of the party by means of (i) any electronic
signature permitted by the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, and/or any other relevant electronic signatures law, including relevant provisions of the
Uniform Commercial Code/UCC (collectively, “Signature Law”); (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature. Each electronic signature or faxed, scanned, or photocopied manual signature
shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no liability with respect to, any faxed,
scanned, or photocopied manual signature, or other electronic signature, of any party and shall have no duty to investigate, confirm or otherwise verify the validity or authenticity thereof. For avoidance of doubt, original manual signatures shall
be used for execution or indorsement of writings when required under the UCC or other Signature Law due to the character or intended character of the writings. 

Section 4.11. Trustee Disclaimer. The Trustee makes no representation as to the validity or sufficiency of this Supplemental
Indenture other than as to the validity of its execution and delivery by the Trustee. The recitals and statements herein are deemed to be those of the Company and the Guarantors and not the Trustee. 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have caused the Supplemental Indenture to be duly
executed as of the day and year first above written. 
  
  

					
	MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à.r.l. its General
Partner, in turn acting by
		
	By:	 	/s/ Erik De Gres
		 	Name:	 	Erik De Gres
		 	Title:	 	Managing Director and authorized signatory

 Attest: 
  

					
	By:	 	/s/ Salvador Sens
		 	Name:	 	Salvador Sens
		 	Title:	 	Managing Director and authorized signatory of Medtronic Global Holdings S.C.A.

  
 [Signature Page to
Medtronic Global Holdings S.C.A. Fifth Supplemental Indenture] 

 
					
	MEDTRONIC PUBLIC LIMITED COMPANY
		
	By:	 	/s/ Jason Bristow
		 	Name:	 	Jason Bristow
		 	Title:	 	Treasurer

  
 [Signature Page to
Medtronic Global Holdings S.C.A. Fifth Supplemental Indenture] 

 
					
	 MEDTRONIC, INC.

		
	By:	 	/s/ Jason Bristow
		 	 Name:
	 	 Jason Bristow

		 	 Title:
	 	Treasurer

  
 [Signature Page to
Medtronic Global Holdings S.C.A. Fifth Supplemental Indenture] 

 
			
	 COMPUTERSHARE TRUST COMPANY, N.A., Trustee

		
	By:	 	/s/ Jessica Wuornos
		 	Name: Jessica Wuornos
		 	Title:Vice President

  
 [Signature Page to
Medtronic Global Holdings S.C.A. Fifth Supplemental Indenture] 

 
			
	 ELAVON FINANCIAL SERVICES DAC, as Paying Agent

		
	By:	 	/s/ Liliya Popova
		 	 Name: Liliya Popova

		 	 Title:   Authorised Signatory

  
 [Signature Page to
Medtronic Global Holdings S.C.A. Fifth Supplemental Indenture] 

 EXHIBIT A 

FORM OF NOTE 
 THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (“EUROCLEAR”) AND CLEARSTREAM BANKING,
S.A. (“CLEARSTREAM” AND, TOGETHER WITH EUROCLEAR, “EUROCLEAR/CLEARSTREAM”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 

 MEDTRONIC GLOBAL HOLDINGS S.C.A. 

2.625% Senior Note Due 2025 
  

					
	No.	  		  	 CUSIP No.: 58507L AX7

ISIN No.: XS2535307743
 COMMON CODE:
253530774

		  		  	€        

 Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en
commandite par actions) incorporated and existing under the laws of the Grand Duchy of Luxembourg (herein called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for
value received, hereby promises to pay to USB Nominees (UK) Limited or registered assigns, the principal sum of     Euros on October 15, 2025 and to pay interest thereon from September 21, 2022 or from the most recent
Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October 15 in each year, commencing October 15, 2023, at the rate of 2.625% per annum, until the principal hereof is paid or made available
for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by this Security. 

The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid
to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not so punctually paid
or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security is registered at the close of business on a Special Record Date for the payment of
such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent
with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. 

Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the office or agency of the Paying
Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the
Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or other circumstances beyond its control or the Euro is no longer used by the then
member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the 2025 Notes
will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted by the Company into U.S. Dollars at the rate mandated by the U.S. Federal
Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S. Dollar/Euro exchange
rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published such exchange rate, the rate will be determined in the Company’s sole
discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2025 Notes so made in U.S. Dollars will not constitute an Event of Default. Neither the Trustee
nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. 

 Reference is hereby made to the further provisions of this Security set forth on the reverse
hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of
authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à.r.l. its General
Partner, in turn acting by
		
	By:	 	 
		 	Name:
		 	Title:

 Attest: 

 NOTATION OF GUARANTEE 

For value received, the undersigned (the “Guarantor”), to the extent set forth in and subject to the terms of the Indenture,
dated as of March 28, 2017 (the “Base Indenture”), among Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en commandite par actions) incorporated and existing under the
laws of the Grand Duchy of Luxembourg (the “Company”), Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland (“Medtronic plc”), Medtronic, Inc., a Minnesota corporation
(“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the
Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, hereby fully and unconditionally guarantees, on a joint and several basis, to each Holder and to the Trustee and its
successors and assigns, that the principal of and premium, if any, and interest on the 2025 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of
and interest on the 2025 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or performed. 

The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture are expressly set
forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2025 Notes to which this Notation of Guarantee is endorsed, by accepting such
2025 Notes, agrees to and shall be bound by such provisions. 
 All terms used in this Notation of Guarantee which are defined in the
Indenture shall have the meanings assigned to them in the Indenture. 

 IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. 
 Dated:            , 20 

 

			
	 MEDTRONIC PUBLIC LIMITED COMPANY

		
	By	 	 
	
	 MEDTRONIC, INC.

		
	By	 	 

 This is one of the Securities of the series designated herein and referred to in the
within-mentioned Indenture. 
 Dated:             , 20 

 

			
	 COMPUTERSHARE TRUST COMPANY,
 N.A.,
Trustee

		
	By:	 	 
		 	Authorized Signatory

 (REVERSE OF SECURITY) 

MEDTRONIC GLOBAL HOLDINGS S.C.A. 

2.625% Senior Note Due 2025 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to
be issued in one or more series under an Indenture, dated as of March 28, 2017 (the “Base Indenture”), among the Company, Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland
(“Medtronic plc”), Medtronic, Inc., a Minnesota corporation (“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the
“Trustee”, which term includes any successor trustee under the Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental
Indenture” and, together with the Base Indenture, the “Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, and reference is hereby made to the Indenture for a
statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.
This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to €500,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the same
terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred and is continuing with respect to the Securities. 

The Securities of this series may be redeemed at any time prior to the applicable Par Call Date, as a whole or in part, at the option of the
Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal to the greater of: 

(i) 100% of the principal amount of the Securities being redeemed; and 

(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 20 basis points; 
 plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. 
 In addition, at any time on and after the applicable Par Call Date, the Securities are redeemable at the
Company’s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

 In the event of redemption of this Security in part only, a new Security or Securities of
this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series
may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture permits, with certain
exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and
the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in
principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the
Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer
hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 As
provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy
thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this
series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in
compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to
institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or
any premium or interest hereon on or after the respective due dates expressed herein. 
 As provided in the Indenture and subject to certain
limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any
premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder’s attorney
duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

 The Securities of this series are issuable only in registered form without coupons in
denominations of €100,000 or an integral multiple of €1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. 
 All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. 

 EXHIBIT B 

FORM OF NOTE 
 THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (“EUROCLEAR”) AND CLEARSTREAM BANKING,
S.A. (“CLEARSTREAM” AND, TOGETHER WITH EUROCLEAR, “EUROCLEAR/CLEARSTREAM”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 

 MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.000% Senior Note Due 2028 
  

			
		 	CUSIP No.: 58507L AY5
	No.	 	ISIN No.: XS2535308477
		 	COMMON CODE: 253530847
		 	€            

 Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en
commandite par actions) incorporated and existing under the laws of the Grand Duchy of Luxembourg (herein called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for
value received, hereby promises to pay to USB Nominees (UK) Limited or registered assigns, the principal sum of             Euros on October 15, 2028 and to pay interest thereon from
September 21, 2022 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October 15 in each year, commencing October 15, 2023, at the rate of 3.000% per annum, until
the principal hereof is paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any applicable grace periods) to the extent lawful, from time to time on
demand at the rate borne by this Security. 
 The interest so payable, and punctually paid or duly provided for, on any Interest Payment
Date will, as provided in such Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which shall be the Business Day immediately preceding such Interest
Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security is registered at the close of
business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any
time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said
Indenture. 
 Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the office or agency
of the Paying Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the Company payment of interest may be made by check mailed to the
address of the Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or other circumstances beyond its control or the Euro is no longer
used by the then member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of
the 2028 Notes will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted by the Company into U.S. Dollars at the rate mandated by the
U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S.
Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published such exchange rate, the rate will be determined in
the Company’s sole discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2028 Notes so made in U.S. Dollars will not constitute an Event of
Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. 

 Reference is hereby made to the further provisions of this Security set forth on the reverse
hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of
authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à.r.l. its General
Partner, in turn acting by
		
	By:	 	 
		 	 Name:

		 	 Title:

 Attest: 

 NOTATION OF GUARANTEE 

For value received, the undersigned (the “Guarantor”), to the extent set forth in and subject to the terms of the Indenture,
dated as of March 28, 2017 (the “Base Indenture”), among Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en commandite par actions) incorporated and existing under the
laws of the Grand Duchy of Luxembourg (the “Company”), Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland (“Medtronic plc”), Medtronic, Inc., a Minnesota corporation
(“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the
Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, hereby fully and unconditionally guarantees, on a joint and several basis, to each Holder and to the Trustee and its
successors and assigns, that the principal of and premium, if any, and interest on the 2028 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of
and interest on the 2028 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or performed. 

The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture are expressly set
forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2028 Notes to which this Notation of Guarantee is endorsed, by accepting such
2028 Notes, agrees to and shall be bound by such provisions. 
 All terms used in this Notation of Guarantee which are defined in the
Indenture shall have the meanings assigned to them in the Indenture. 

 IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. 
 Dated:            , 20 

 

			
	 MEDTRONIC PUBLIC LIMITED COMPANY

		
	By	 	 
	
	MEDTRONIC, INC.
		
	By	 	 

 This is one of the Securities of the series designated herein and referred to in the
within-mentioned Indenture. 
 Dated:            , 20 

 

			
	 COMPUTERSHARE TRUST COMPANY,

N.A., Trustee

		
	By:	 	 
		 	Authorized Signatory

 (REVERSE OF SECURITY) 

MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.000% Senior Note Due 2028 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to
be issued in one or more series under an Indenture, dated as of March 28, 2017 (the “Base Indenture”), among the Company, Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland
(“Medtronic plc”), Medtronic, Inc., a Minnesota corporation (“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the
“Trustee”, which term includes any successor trustee under the Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental
Indenture” and, together with the Base Indenture, the “Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, and reference is hereby made to the Indenture for a
statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.
This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to €1,000,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the
same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred and is continuing with respect to the Securities. 

The Securities of this series may be redeemed at any time prior to the applicable Par Call Date, as a whole or in part, at the option of the
Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal to the greater of: 

(i) 100% of the principal amount of the Securities being redeemed; and 

(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 25 basis points; 
 plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. 
 In addition, at any time on and after the applicable Par Call Date, the Securities are redeemable at the
Company’s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

 In the event of redemption of this Security in part only, a new Security or Securities of
this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series
may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture permits, with certain
exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and
the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in
principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the
Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer
hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 As
provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy
thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this
series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in
compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to
institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or
any premium or interest hereon on or after the respective due dates expressed herein. 
 As provided in the Indenture and subject to certain
limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any
premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder’s attorney
duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

 The Securities of this series are issuable only in registered form without coupons in
denominations of €100,000 or an integral multiple of €1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. 
 All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. 

 EXHIBIT C 

FORM OF NOTE 
 THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (“EUROCLEAR”) AND CLEARSTREAM BANKING,
S.A. (“CLEARSTREAM” AND, TOGETHER WITH EUROCLEAR, “EUROCLEAR/CLEARSTREAM”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 

 MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.125% Senior Note Due 2031 
  

			
		  	CUSIP No.: 58507L AZ2
	No.	  	ISIN No.: XS2535308634
		  	COMMON CODE: 253530863
		  	€        

 Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en
commandite par actions) incorporated and existing under the laws of the Grand Duchy of Luxembourg (herein called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for
value received, hereby promises to pay to USB Nominees (UK) Limited or registered assigns, the principal sum of         Euros on October 15, 2031 and to pay interest thereon from September 21, 2022
or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October 15 in each year, commencing October 15, 2023, at the rate of 3.125% per annum, until the principal hereof is
paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by
this Security. 
 The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such
Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not
so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security is registered at the close of business on a Special Record Date for
the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. 

Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the office or agency of the Paying
Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the
Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or other circumstances beyond its control or the Euro is no longer used by the then
member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the 2031 Notes
will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted by the Company into U.S. Dollars at the rate mandated by the U.S. Federal
Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S. Dollar/Euro exchange
rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published such exchange rate, the rate will be determined in the Company’s sole
discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2031 Notes so made in U.S. Dollars will not constitute an Event of Default. Neither the Trustee
nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. 

 Reference is hereby made to the further provisions of this Security set forth on the reverse
hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of
authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à.r.l. its General
Partner, in turn acting by
		
	By:	 	 
		 	Name:
		 	Title:

 Attest: 

 NOTATION OF GUARANTEE 

For value received, the undersigned (the “Guarantor”), to the extent set forth in and subject to the terms of the Indenture,
dated as of March 28, 2017 (the “Base Indenture”), among Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en commandite par actions) incorporated and existing under the
laws of the Grand Duchy of Luxembourg (the “Company”), Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland (“Medtronic plc”), Medtronic, Inc., a Minnesota corporation
(“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the
Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, hereby fully and unconditionally guarantees, on a joint and several basis, to each Holder and to the Trustee and its
successors and assigns, that the principal of and premium, if any, and interest on the 2031 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of
and interest on the 2031 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or performed. 

The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture are expressly set
forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2031 Notes to which this Notation of Guarantee is endorsed, by accepting such
2031 Notes, agrees to and shall be bound by such provisions. 
 All terms used in this Notation of Guarantee which are defined in the
Indenture shall have the meanings assigned to them in the Indenture. 

 IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. 
 Dated:        , 20 

 

			
	MEDTRONIC PUBLIC LIMITED COMPANY
		
	By	 	 
	
	MEDTRONIC, INC.
		
	By	 	 

 This is one of the Securities of the series designated herein and referred to in the
within-mentioned Indenture. 
 Dated:             , 20 

 

			
	COMPUTERSHARE TRUST COMPANY, N.A., Trustee
		
	By:	 	 
		 	Authorized Signatory

 (REVERSE OF SECURITY) 

MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.125% Senior Note Due 2031 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to
be issued in one or more series under an Indenture, dated as of March 28, 2017 (the “Base Indenture”), among the Company, Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland
(“Medtronic plc”), Medtronic, Inc., a Minnesota corporation (“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the
“Trustee”, which term includes any successor trustee under the Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental
Indenture” and, together with the Base Indenture, the “Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, and reference is hereby made to the Indenture for a
statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.
This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to €1,000,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the
same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred and is continuing with respect to the Securities. 

The Securities of this series may be redeemed at any time prior to the applicable Par Call Date, as a whole or in part, at the option of the
Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal to the greater of: 

(i) 100% of the principal amount of the Securities being redeemed; and 

(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 25 basis points; 
 plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. 
 In addition, at any time on and after the applicable Par Call Date, the Securities are redeemable at the
Company’s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

 In the event of redemption of this Security in part only, a new Security or Securities of
this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series
may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture permits, with certain
exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and
the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in
principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the
Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer
hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 As
provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy
thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this
series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in
compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to
institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or
any premium or interest hereon on or after the respective due dates expressed herein. 
 As provided in the Indenture and subject to certain
limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any
premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder’s attorney
duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

 The Securities of this series are issuable only in registered form without coupons in
denominations of €100,000 or an integral multiple of €1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. 
 All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. 

 EXHIBIT D 

FORM OF NOTE 
 THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (“EUROCLEAR”) AND CLEARSTREAM BANKING,
S.A. (“CLEARSTREAM” AND, TOGETHER WITH EUROCLEAR, “EUROCLEAR/CLEARSTREAM”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 

 MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.375% Senior Note Due 2034 
  

			
		  	CUSIP No.: 58507L BA6
	No.	  	ISIN No.: XS2535309798
		  	COMMON CODE: 253530979
		  	€        

 Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en
commandite par actions) incorporated and existing under the laws of the Grand Duchy of Luxembourg (herein called the “Company”, which term includes any successor corporation under the Indenture hereinafter referred to), for
value received, hereby promises to pay to USB Nominees (UK) Limited or registered assigns, the principal sum of         Euros on October 15, 2034 and to pay interest thereon from September 21, 2022
or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October 15 in each year, commencing October 15, 2023, at the rate of 3.375% per annum, until the principal hereof is
paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by
this Security. 
 The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such
Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not
so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security is registered at the close of business on a Special Record Date for
the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. 

Payment of the principal of (and premium, if any) and any such interest on this Security will be made at the office or agency of the Paying
Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the
Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or other circumstances beyond its control or the Euro is no longer used by the then
member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the 2034 Notes
will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted by the Company into U.S. Dollars at the rate mandated by the U.S. Federal
Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S. Dollar/Euro exchange
rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published such exchange rate, the rate will be determined in the Company’s sole
discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2034 Notes so made in U.S. Dollars will not constitute an Event of Default. Neither the Trustee
nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. 

 Reference is hereby made to the further provisions of this Security set forth on the reverse
hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of
authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à.r.l. its General
Partner, in turn acting by
		
	By:	 	 
		 	Name:
		 	Title:

 Attest: 

 NOTATION OF GUARANTEE 

For value received, the undersigned (the “Guarantor”), to the extent set forth in and subject to the terms of the Indenture,
dated as of March 28, 2017 (the “Base Indenture”), among Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (société en commandite par actions) incorporated and existing under the
laws of the Grand Duchy of Luxembourg (the “Company”), Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland (“Medtronic plc”), Medtronic, Inc., a Minnesota corporation
(“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the
Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental Indenture” and, together with the Base Indenture, the
“Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, hereby fully and unconditionally guarantees, on a joint and several basis, to each Holder and to the Trustee and its
successors and assigns, that the principal of and premium, if any, and interest on the 2034 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of
and interest on the 2034 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or performed. 

The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture are expressly set
forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2034 Notes to which this Notation of Guarantee is endorsed, by accepting such
2034 Notes, agrees to and shall be bound by such provisions. 
 All terms used in this Notation of Guarantee which are defined in the
Indenture shall have the meanings assigned to them in the Indenture. 

 IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. 
 Dated:            , 20 

 

			
	 MEDTRONIC PUBLIC LIMITED COMPANY

		
	By	 	 
	
	 MEDTRONIC, INC.

		
	By	 	 

 This is one of the Securities of the series designated herein and referred to in the
within-mentioned Indenture. 
 Dated:            , 20 

 

			
	COMPUTERSHARE TRUST COMPANY, N.A., Trustee
		
	By:	 	 
		 	Authorized Signatory

 (REVERSE OF SECURITY) 

MEDTRONIC GLOBAL HOLDINGS S.C.A. 

3.375% Senior Note Due 2034 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to
be issued in one or more series under an Indenture, dated as of March 28, 2017 (the “Base Indenture”), among the Company, Medtronic Public Limited Company, a public limited company incorporated under the laws of Ireland
(“Medtronic plc”), Medtronic, Inc., a Minnesota corporation (“Medtronic, Inc.”), and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as Trustee (herein called the
“Trustee”, which term includes any successor trustee under the Indenture (as defined below)), and as amended and supplemented by the Fifth Supplemental Indenture, dated as of September 21, 2022 (the “Fifth Supplemental
Indenture” and, together with the Base Indenture, the “Indenture”), among the Company, Medtronic plc, Medtronic, Inc., the Trustee and Elavon Financial Services DAC, and reference is hereby made to the Indenture for a
statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.
This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to €1,000,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the
same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred and is continuing with respect to the Securities. 

The Securities of this series may be redeemed at any time prior to the applicable Par Call Date, as a whole or in part, at the option of the
Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal to the greater of: 

(i) 100% of the principal amount of the Securities being redeemed; and 

(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 25 basis points; 
 plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. 
 In addition, at any time on and after the applicable Par Call Date, the Securities are redeemable at the
Company’s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

 In the event of redemption of this Security in part only, a new Security or Securities of
this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series
may be declared due and payable in the manner and with the effect provided in the Indenture. 
 The Indenture permits, with certain
exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and
the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in
principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the
Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer
hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 As
provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy
thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this
series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in
compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to
institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or
any premium or interest hereon on or after the respective due dates expressed herein. 
 As provided in the Indenture and subject to certain
limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any
premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder’s attorney
duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 

  
 56 

 The Securities of this series are issuable only in registered form without coupons in
denominations of €100,000 or an integral multiple of €1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. 
 All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. 

  
 57thcc_ex101.htm

  EXHIBIT 10.1
  
 LOAN PURCHASE AND SALE AGREEMENT
  
  THIS LOAN PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into effective as of September 09, 2022 (the “Effective Date”) by and between CircleUp Credit Advisors LLC, a Delaware limited liability company (“Seller”), and The Healing Company Inc., a Nevada corporation (“Buyer”). Capitalized terms used but not otherwise defined herein shall have their respective meanings set forth in Schedule 1 attached hereto and incorporated herein by reference.
  
 RECITALS
  
 WHEREAS, Seller is the owner and holder of the Loan and the Loan Documents each as defined in Schedule 1 attached hereto; and
  
 WHEREAS, Buyer desires to purchase the Loan and the Loan Documents from Seller, and Seller desires to sell the Loan and the Loan Documents to Buyer, in accordance with the terms and conditions set forth herein.
  
 NOW THEREFORE, in consideration of the foregoing premises and mutual agreements herein contained, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, Buyer and Seller agree as follows:
  
 ARTICLE 1 PURCHASE AND SALE
  
 Section 1.1  Agreement to Purchase and Sell the Loan Rights and Obligations. Subject to the satisfaction of the conditions set forth in Sections 4.1 and 4.2 below, on the Closing Date, Seller shall sell, transfer and assign to Buyer, and Buyer shall buy and assume the Loan Rights and Obligations, all as more particularly described herein. Not later than 2:00 p.m. New York City time on the Closing Date, Buyer shall deliver to Seller (i) the Cash Purchase Price by wire transfer of immediately available funds in accordance with Seller’s wire transfer instructions set forth on Exhibit F hereto and (ii) the Warrant. The Loan will be sold to Buyer on a servicing released basis. The Loan, Loan Documents and Loan Rights and Obligations assigned to and assumed by Buyer as of the Closing shall include, without limitation, all of Seller’s rights and obligations with respect to the servicing of the Loan as of the Closing, and Seller will be discharged from all obligations with respect to the servicing of the Loan, whether arising before or after the Closing Date. The last sentence of this Section 1.1 shall survive the Closing.
  
 ARTICLE 2
 REPRESENTATIONS, WARRANTIES AND COVENANTS OF BUYER
  
 Buyer hereby represents, warrants and covenants for the benefit of Seller and in order to induce Seller to enter into this Agreement that as of the date hereof and as of the Closing Date:
  
  
 
 
 
 
 
 	 
	
	

	 

 
 
  
 
 
 
 
 Section 2.1  Authorization and Compliance. Buyer is a corporation validly existing and in good standing under the laws of the State of Nevada. Buyer is duly and legally authorized to execute, deliver, and perform its obligations under this Agreement and the Buyer’s Closing Documents hereunder, and the undersigned representative is authorized to act on behalf of Buyer, and bind Buyer to, the terms of this Agreement. Buyer is not required to obtain the consent of any other Person in connection with Buyer’s execution, delivery, or performance of this Agreement, except such as have been obtained and are in full force and effect.
  
 Section 2.2 Binding Obligation of Buyer. Assuming due authorization, execution and delivery by Seller, this Agreement and all of the obligations of Buyer hereunder are, and at Closing all of Buyer’s Closing Documents required to be delivered hereunder will be, the legal, valid and binding obligations of Buyer, enforceable in accordance with the terms of this Agreement or the applicable Buyer’s Closing Documents, except as such enforcement may be limited by bankruptcy, insolvency, reorganization or other similar laws affecting the enforcement of creditors’ rights generally and by general equity principles (regardless of whether such enforcement is considered in a proceeding in equity or at law).
  
 Section 2.3  Prohibited Person. Buyer represents and warrants that: (i) Buyer is not, nor is it owned (directly or indirectly) or Controlled by, any Person named on any list issued by the Office of Foreign Assets Control of the United States Department of the Treasury (“OFAC”) pursuant to Executive Order 13224 or any similar list or any law, order, rule or regulation or any Executive Order of the President of the United States as a terrorist, “Specially Designated National and Blocked Person” or other banned or blocked Person (any such Person being hereinafter referred to as a “Prohibited Person”); (ii) Buyer is not (nor is it owned (directly or indirectly) or Controlled by any Person which is) acting directly or indirectly for or on behalf of any Prohibited Person; and (iii) Buyer has not nor is it owned (directly or indirectly) or Controlled by any Person which has conducted business or engaged in any transaction or dealing with any Prohibited Person in violation of the Patriot Act or any OFAC rule or regulation, including without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of a Prohibited Person in violation of the Patriot Act or any OFAC rule or regulation. Notwithstanding anything contained herein to the contrary, for the purposes of this Section 2.3, the phrase “owned (directly or indirectly) or Controlled by, any Person” and all similar such phrases shall not include any holder of a direct or indirect interest in a publicly traded company whose shares are listed and traded on a U.S. national stock exchange. For purposes of this Section 2.3, “Control” or “Controlled” means, with respect to a Person, the power (directly or indirectly) to direct the actions or policies of such Person by ownership of voting securities, as its general partner, manager or managing member, by contract, or by other means. Buyer represents and warrants that any information provided by Buyer to Seller with respect to the identity of Persons that own a direct or indirect equity interest in Buyer is true and accurate.
  
 Section 2.4 Independent Evaluation; Sophisticated Investor. Buyer is a sophisticated, experienced investor. Buyer’s decision to purchase the Loan and Loan Documents and assume the Loan Rights and Obligations pursuant to this Agreement is based upon Buyer’s own independent evaluation of the Loan Documents, the Loan File, the Collateral and all publicly-available information, which Buyer acknowledges and agrees were available to it and which it was given the opportunity to review and inspect. Buyer has relied and shall rely solely on its own investigation of the Loan Documents and the foregoing materials, and it has not relied and shall not rely upon any oral or written statements, representations, opinions, analyses, or information provided by Seller, or its personnel, agents, attorneys, consultants, servicers, operating advisors, other advisors and consultants, or brokers, and acknowledges that no employee or representative of Seller has been authorized to make, that no such Person has made, and that Buyer has not relied upon and shall not rely upon, any statements or representations concerning the Loan Documents or such other materials other than those representations specifically set forth in Sections 3.1 through 3.5 below (collectively, the “Seller’s Representations”). Buyer is acquiring the Loan Rights and Obligations for its own account and not as a broker, finder or similar agent for any other Person or with the intent to resell the Loan Rights and Obligations.
  
  
 
 
 
 
 
 	 
	2
	

	 

 
 
  
 
 
 
 
 Section 2.5 “AS-IS” SALE. EXCEPT AS PROVIDED IN THE SELLER’S REPRESENTATIONS, BUYER ACKNOWLEDGES AND AGREES THAT SELLER HAS NOT AND DOES NOT REPRESENT, WARRANT OR COVENANT AS TO ANY CONDITION OR STATUS OF THE LOAN, THE LOAN DOCUMENTS, OR THE COLLATERAL, OR THE NATURE, ACCURACY, COMPLETENESS OR VALIDITY OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE MATERIALS IN THE LOAN FILE, ALL OF WHICH ARE BEING SOLD, TRANSFERRED, ASSIGNED AND CONVEYED TO BUYER ON AN “AS IS, WHERE IS” BASIS, WITH ALL FAULTS, AND EXCEPT AS EXPRESSLY PROVIDED IN THE SELLER’S REPRESENTATIONS, WITHOUT REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY TYPE, KIND, CHARACTER OR NATURE (INCLUDING, WITHOUT LIMITATION, AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). WITHOUT LIMITING THE FOREGOING, BUYER EXPRESSLY ACKNOWLEDGES AND AGREES THAT NO ORAL OR WRITTEN STATEMENTS, WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED, HAVE BEEN MADE BY SELLER OR BY ANYONE ACTING ON ITS BEHALF, REGARDING (A) THE COLLECTABILITY OF THE LOAN, (B) THE CREDITWORTHINESS OF ANY OBLIGOR, (C) THE VALUE OF ANY OF THE LOAN DOCUMENTS OR ANY COLLATERAL SECURING PAYMENT OF THE LOAN, (D) TITLE TO OR THE CONDITION OF THE COLLATERAL, INCLUDING BUT NOT LIMITED TO, ANY ENVIRONMENTAL MATTER OR CONDITION, WHETHER LATENT OR OBSERVABLE, (E) THE ACCURACY, COMPLETENESS, OR RELIABILITY OF ANY DOCUMENTS, MATERIALS OR INFORMATION CONTAINED IN THE LOAN FILE OR ANY OTHER DOCUMENTS OR MATERIALS DELIVERED TO BUYER OR ITS REPRESENTATIVES, AND BUYER EXPRESSLY ACKNOWLEDGES THAT SELLER IS NEITHER TRANSFERRING NOR MAKING AVAILABLE SELLER’S ENTIRE FILE REGARDING THE LOAN, (F) THE ACCURACY OR COMPLETENESS OF THE LOAN DOCUMENTS, OR THEIR CONFORMITY TO ANY ORIGINALS THEREOF, OR THE AUTHENTICITY OF ANY DOCUMENT AS AN ORIGINAL, (G) THE VALIDITY, PRIORITY, PERFECTION, SUFFICIENCY, ENFORCEABILITY, OR EFFECTIVENESS OF ANY LOAN DOCUMENT OR ANY LIEN CREATED BY ANY LOAN DOCUMENT, (H) THE FINANCIAL CONDITION OR PERFORMANCE OF ANY PERSON OBLIGATED WITH RESPECT TO THE LOAN OR THE COLLATERAL AND/OR (I) THE COMPLIANCE OR CONFORMITY OF THE LOAN WITH ANY LENDING OR UNDERWRITING CRITERIA OR PRACTICES. FROM AND AFTER THE CLOSING DATE, BUYER ASSUMES ALL RISK OF LOSS IN CONNECTION WITH THE LOAN AND THE LOAN RIGHTS AND OBLIGATIONS. THE PURCHASE PRICE AND THE TERMS AND CONDITIONS SET FORTH HEREIN ARE THE RESULT OF ARM’S LENGTH BARGAINING BETWEEN ENTITIES FAMILIAR WITH TRANSACTIONS OF THIS KIND, AND REFLECT THE FACT THAT BUYER SHALL HAVE THE BENEFIT, AND IS RELYING UPON NO INFORMATION PROVIDED BY SELLER AND EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, THE LOAN AND THE LOAN RIGHTS AND OBLIGATIONS ASSIGNED TO AND ASSUMED BY BUYER UNDER THIS AGREEMENT ARE SOLD AND TRANSFERRED WITHOUT RECOURSE TO SELLER. BUYER UNDERSTANDS AND ACKNOWLEDGES THAT, ALTHOUGH SELLER HAS ATTEMPTED TO PROVIDE BUYER ACCESS TO INFORMATION IN SELLER’S POSSESSION WHICH SELLER BELIEVED COULD BE RELEVANT, SUCH MATERIALS AND INFORMATION MAY BE INCOMPLETE AND/OR OUTDATED AND MAY CONTAIN ERRORS, OMISSIONS, INACCURACIES, AND CONFLICTING INFORMATION, AND THAT SELLER HAS NOT ATTEMPTED TO VERIFY, CORRECT OR RECONCILE ANY SUCH MATERIALS OR INFORMATION. BUYER HAS BEEN ADVISED, AND IS HEREBY EXPRESSLY ADVISED, TO CONDUCT AN INDEPENDENT INVESTIGATION WITH RESPECT TO THE IDENTIFICATION AND SUFFICIENCY OF THE LOAN, THE LOAN DOCUMENTS, THE COLLATERAL, THE VALUE AND CONDITION OF THE FOREGOING, THE LIEN PRIORITY AND PERFECTION OF THE LOAN DOCUMENTS (INCLUDING, WITHOUT LIMITATION, OBTAINING TITLE SEARCHES AND/OR, IF OBTAINABLE, A LENDER’S TITLE POLICY ENDORSEMENT OR NEW LENDER’S TITLE POLICY IN CONNECTION WITH THE COLLATERAL), THE FINANCIAL CONDITION AND MANAGEMENT ABILITY OF THE OBLIGOR(S), THE VALIDITY AND ENFORCEABILITY OF THE LOAN DOCUMENTS, AND ALL OTHER MATTERS WHICH COULD AFFECT THE COLLECTABILITY AND VALUE OF THE LOAN, THE NOTE, THE OTHER LOAN DOCUMENTS, AND THE LOAN RIGHTS AND OBLIGATIONS. BUYER EXPRESSLY ACKNOWLEDGES AND AGREES THAT, IF BUYER CONSUMMATES THE TRANSACTION CONTEMPLATED HEREBY, BUYER WILL BE DOING SO WITHOUT SELLER HAVING TAKEN ANY ACTIONS TO ALLOW BUYER ACCESS OR OPPORTUNITY TO INSPECT THE COLLATERAL, THAT SELLER IS NOT OBLIGATED TO PROVIDE SUCH ACCESS OR OBTAIN OR PROVIDE ANY INFORMATION CONCERNING THE COLLATERAL, INCLUDING, WITHOUT LIMITATION, CONCERNING THE ENVIRONMENTAL CONDITION THEREOF, AND THAT BUYER IS RELYING SOLELY ON ITS OWN INVESTIGATIONS (OR HAS DECIDED TO PROCEED AT ITS OWN RISK WITHOUT ANY SUCH INVESTIGATIONS) OF THE COLLATERAL.
  
  
 
 
 	 
	
	

	 

 
 
  
 
 
 
 
 Section 2.6 Release of Seller. Buyer, on behalf of itself, its successors, assigns and affiliates, and any Person claiming by, through or under Buyer (collectively, the “Releasing Parties”), hereby releases and forever discharges Seller and all affiliates of, and any holders of any direct or indirect interest in (including, without limitation, all certificate holders) Seller, and Seller’s officers, directors, shareholders, members, principals, managers, employees, representatives, agents, servicers, operating advisors, other advisors and consultants, predecessors, successors and assigns, and all Persons acting on their behalf (all such Persons being collectively referred to as the “Released Parties”), of and from any and all causes of action, claims, demands, obligations, liabilities, indebtedness, breaches of contract, breaches of duty or any relationship, acts, omissions, misfeasance, malfeasance, judgments, debts, controversies, damages, costs, losses and expenses, and remedies of whatsoever kind and nature that Buyer or any other Releasing Party has or may in the future have against Seller or any other Released Parties, and in any manner on account of, arising out of or related (directly or indirectly) to the transactions contemplated by this Agreement, any Obligor, the Loan, the Loan Documents, the Loan File and the Collateral, whether known or unknown, past, present or future, latent or patent, suspected or unsuspected, anticipated or unanticipated) (the “Released Matters”); provided, however, that the Released Matters shall not include, and Buyer does not release Seller or any Released Party from, any claims or causes of action arising by reason of Seller’s breach of this Agreement (including, without limitation, any breach of the Seller’s Representations). The foregoing waiver and release includes claims of which the Releasing Parties are presently unaware or which the Releasing Parties do not presently suspect to exist which, if known by the Releasing Parties, would materially affect the Releasing Parties’ release of the Released Parties, and including without limitation any and all claims that are direct and/or indirect, contingent or matured, or of whatever kind or nature, for or because of any matter or things done, omitted or permitted to be done by any of the Released Parties, at law or in equity. Buyer on behalf of itself and each other Releasing Parties (a) understands, acknowledges and agrees that the waiver and release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against or dismissal of any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release, (b) agrees that no fact, event, circumstance, evidence, or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the waiver and release set forth above, (c) agrees, represents and warrants that each realizes and acknowledges that factual matters now unknown to them may have given or may hereafter give rise to causes of action, claims, demands, debts, controversies, damages, costs, losses and expenses which are presently unknown, unanticipated and unsuspected, and each further agrees, represents and warrants that this release has been negotiated and agreed upon in light of that realization and that the Releasing Parties nevertheless hereby intend to release, discharge and acquit the Released Parties from any and all such unknown causes of action, claims, demands, debts, controversies, damages, costs, losses and expenses which in any way arise out of, are connected with, or relate to, any Obligor, the Loan, the Loan Documents, the Collateral or any remedial action taken by Seller in connection therewith. It is hereby further understood and agreed that the acceptance of delivery of this Agreement by the Seller shall not be deemed or construed as an admission of liability by any party released by the terms hereof, and Seller on behalf of itself and each such other party hereby expressly denies liability of any nature whatsoever arising from or related to the subject of the foregoing release. Buyer hereby represents and warrants that (i) it owns all of the purported claims, rights, demands and causes of action that are being released by the foregoing release and that no other Person has any interest in said claims, rights, demands or causes of action whether by reason of any contract or dealing with the Releasing Parties or otherwise, and (ii) Buyer has not assigned to any other Person all or any part of such claims, rights, demands or causes of action. Buyer hereby acknowledges, represents and warrants that it has had advice of counsel of its own choosing in negotiations for and the preparation of the foregoing release, that it has read the foregoing release or has had the same read to it by its counsel, that it has had the within release fully explained by such counsel, and that it is fully aware of its contents and legal effect.
  
  
 
 
 
 
 
 	 
	4
	

	 

 
 
  
 
 
 
 
 Section 2.7  Indemnification. Buyer hereby agrees to, upon Closing, indemnify, defend, and hold Seller and the other Released Parties (collectively, the “Seller Indemnified Parties”), and each of them, harmless from and against any and all losses, causes of action, liabilities, claims, demands, obligations, damages, costs and expenses (including reasonable attorneys’ and accountants’ fees and costs) (collectively, “Claims”) to which any of the Seller
  
 Indemnified Parties is or may become subject on account of, arising out of, or related (directly or indirectly) to (a) any breach of any Buyer representation, warranty or covenant contained in this Agreement or in the Buyer’s Closing Documents and (b) matters occurring on or after the Closing Date and otherwise related to Borrower, guarantors, the Loan, the Loan Documents, the Loan File, the Collateral and/or any litigation pertaining thereto initiated after the Closing Date, in each case with respect to the foregoing, not including Claims to the extent caused solely and directly by the fraud, gross negligence or willful misconduct of such Seller Indemnified Party.
  
 Section 2.8  No Further Reliance on Seller. Except as set forth herein, Buyer is not relying upon the continued actions or efforts of Seller in connection with its decision to purchase the Loan and the Loan Documents and to purchase and assume the Loan Rights and Obligations. Furthermore, Buyer acknowledges and agrees that, in respect of the Loan and the Loan Documents, Buyer may ultimately receive from the Obligor(s) an amount less than the Purchase Price and, except as otherwise expressly set forth in Section 3.6, that Buyer shall have no recourse against Seller or any of the other Released Parties for such deficiency.
  
 Section 2.9  Conformity to Law. From and after the Closing Date, Buyer shall abide by all applicable state and federal laws, rules and regulations regarding the handling and maintenance of all documents and records relating to the Loan, including, but not limited to, the length of time such documents and records are to be retained; provided that the foregoing shall be supplemental to and not in derogation of the provisions of any prior written agreement concerning confidentiality entered into by Buyer or its Affiliates, including, without limitation, that certain Confidentiality Agreement dated as of August 30, 2022, entered into by Buyer (the “Confidentiality Agreement”). After transfer of the Loan Documents to Buyer pursuant to the terms of this Agreement, Buyer agrees that Seller may retain copies of the Loan Documents, and the contents of Seller’s Loan File, and that Seller shall have the continuing right at its own expense to use, inspect, and make extracts from or copies of any such documents or records, upon Seller’s reasonable notice to Buyer. Buyer further agrees to allow Seller the possession, custody and use of original documents from the Loan Documents for any lawful purposes and upon reasonable terms and conditions. Before destruction or disposition of any documents constituting the Loan Documents, Buyer agrees to give reasonable notice to Seller and to allow Seller, at its own expense, to recover the same from Buyer.
  
 Section 2.10 Survival. The rights and obligations of the parties hereto under the provisions of this Article 2 shall survive any Closing.
  
 ARTICLE 3
 REPRESENTATIONS, WARRANTIES AND COVENANTS OF SELLER
  
 Seller hereby represents, warrants and covenants as of the Effective Date that:
  
 Section 3.1  Title to the Loan. Seller is the sole owner and holder of the Loan and Seller has the authority and right to sell and assign the Loan Rights and Obligations to Buyer. The Loan Rights and Obligations are being transferred free and clear of any and all liens, pledges, charges or security interests of any nature created by Seller and Seller has not sold a participation in the Loan Rights and Obligations. Buyer acknowledges, however, that the Collateral may be subject to liens, pledges, participations, charges and security interests in addition to any lien, pledge, participation, charge or security interest created pursuant to the Loan Documents.
  
  
 
 
 
 
 
 	 
	5
	

	 

 
 
  
 
 
 
 
 Section 3.2  Authorization and Compliance. Seller is validly existing under applicable law. Seller is duly and legally authorized to execute, deliver, and perform its obligations under this Agreement and all documents contemplated hereunder, and the undersigned representative is authorized to act on behalf of and bind Seller to the terms of this Agreement.
  
 Section 3.3 Binding Obligation of Seller. Assuming due authorization, execution and delivery by each other party, this Agreement and all of the obligations of Seller hereunder are, and at Closing all documents to be executed and delivered hereunder by Seller will be, the legal, valid and binding obligations of Seller, enforceable in accordance with the terms of this Agreement, except as such enforcement may be limited by bankruptcy, insolvency, reorganization or other similar laws affecting the enforcement of creditors’ rights generally and by general equity principles (regardless of whether such enforcement is considered in a proceeding in equity or at law).
  
 Section 3.4 Loan Information. As of the Effective Date (a) the unpaid principal balance of the Loan is $ 7,457,829.76 and the accrued but unpaid interest on the Loan is $ 156,614.64(not including any late charges, costs of collection, or other sums), (b) the last payment of interest and/or principal received by Seller in respect of the Loan was the monthly payment due on April 29, 2022.Seller confirms that the Obligations stopped accruing interest as of July 22,, 2022.
  
 Section 3.5 Loan Documents. Exhibit A is a list of all material Loan Documents including modifications or amendments thereto. All copies of such Loan Documents provided to Buyer by Seller are true and correct copies of the related Loan Documents in Seller’s possession. Except as provided or contemplated in the documents listed on Exhibit A, as previously disclosed to Buyer in writing or as permitted under Section 3.7 hereunder, Seller has not agreed in writing to further modify any of the Loan Documents, satisfy, cancel, subordinate, or rescind the Loan Documents, release any Collateral from the lien of the applicable Loan Documents in whole or in part, or release any Obligor from its obligations under the Loan Documents in whole or in part.
  
 Section 3.6 Seller’s Indemnity for Breached Representations. Seller hereby agrees to indemnify, defend and hold Buyer and its successors, assigns and affiliates (collectively, the “Buyer Indemnified Parties”), and each of them, harmless from and against any and all Claims to which any of the Buyer Indemnified Parties is or may become subject on account of, arising out of, or related (directly or indirectly) to (a) any material breach by Seller of any material representation, warranty or covenant contained in this Article 3 or in the Seller’s Closing Documents, (b) matters occurring prior to the Closing Date and otherwise related to Seller, guarantors, the Loan, the Loan Documents, the Loan File, any litigation pertaining to the Loan and/or the Collateral, in each case with respect to the foregoing, not including Claims to the extent caused solely and directly by the fraud, gross negligence or willful misconduct of such Buyer Indemnified Party; provided, however, that (a) in no event shall Seller be liable for (and Buyer waives its rights to claim any) consequential, speculative, indirect, special or punitive damages, and (b) that in no event shall Seller’s aggregate liability under this Agreement exceed the Purchase Price.
  
  
 
 
 
 
 
 	 
	6
	

	 

 
 
  
 
 
 
 
 Section 3.7 Seller’s Interim Activities. During the period from the Effective Date through the Closing Date, Seller shall have the right to continue to service and administer the Loan; provided, however, if prior to the Closing Date, Seller desires to modify, waive or terminate any of the provisions of the Loan Documents, release any Collateral or release any Obligor from any obligations under the Loan Documents, Seller shall provide prior written notice thereof to Buyer and obtain Buyer’s written consent, which consent Buyer may grant or withhold in its sole and absolute discretion.
  
 Section 3.8 Guarantors. Seller represents and warrants that there is not any guarantor, surety, or accommodation party guaranteeing payment or performance of any or all of the Obligations.
  
 Section 3.9  UCC Forms. Attached hereto as Schedule 3.8 is a list of all of the UCC-1 Financing Statements that have been filed by the Seller with respect to the Loan and the Collateral along with the filing locations of such Financing Statements. Other than as set forth on Schedule 3.8, the Seller has filed no other UCC-1 Financing Statements with respect to the Loan and the Collateral.
  
 ARTICLE 4
 CONDITIONS PRECEDENT
  
 Section 4.1 Buyer’s Conditions Precedent. Notwithstanding anything in this Agreement to the contrary, Buyer’s obligation to purchase and assume the Loan Rights and Obligations shall be subject to and contingent upon the satisfaction (or waiver by Buyer) of each of the following conditions precedent, prior to or on the Closing Date (“Buyer’s Conditions Precedent”):
  
 (a) All Closing Documents necessary to consummate the transactions contemplated in this Agreement on the Closing Date shall have been executed (as applicable) and delivered to Buyer by Seller as required by this Agreement;
  
 (b) Each and every representation and warranty of Seller contained in this Agreement shall be true and correct as and when made and as of the Closing Date in all material respects;
  
 (c) No injunction, action, restraining order, judgment or other ruling issued by any court of competent jurisdiction or governmental authority, or any other legal restraint or prohibition preventing the consummation of the transactions contemplated hereby shall then be in effect.
  
 Section 4.2 Seller’s Conditions Precedent. Notwithstanding anything in this Agreement to the contrary, Seller’s obligation to sell and assign the Loan Rights and Obligations shall be subject to and contingent upon the satisfaction (or waiver by Seller) of the following conditions precedent prior to or on the Closing Date (“Seller’s Conditions Precedent”):
  
  
 
 
 
 
 
 	 
	7
	

	 

 
 
  
 
 
 
 
 (a) Seller’s receipt of the Cash Purchase Price and the fully executed Warrant, subject only to the concurrent satisfaction of the Buyer’s Conditions Precedent;
  
 (b) All Buyer’s Closing Documents shall have been executed (as applicable) and delivered to Seller by Buyer as required by this Agreement;
  
 (c) Each and every representation and warranty of Buyer contained in this Agreement shall be true and correct as and when made and as of the Closing Date in all material respects;
  
 (d) No injunction, action, restraining order, judgment or other ruling issued by any court of competent jurisdiction or governmental authority, or any other legal restraint or prohibition preventing the consummation of the transactions contemplated hereby shall then be in effect; and
  
 (e) Buyer has provided all information (which information Buyer hereby represents, warrants and covenants to be true, accurate and complete) requested by Seller to perform Seller’s due diligence on Buyer and Seller’s diligence regarding Buyer has not revealed any information regarding Buyer or its principals, officers, directors, or direct or indirect owners that would fail to satisfy, in Seller’s determination, Seller’s (including for the purposes of this sentence, the controlling party and the beneficial owner of Seller) internal due diligence approval criteria for Seller’s consummation of the transactions contemplated by this Agreement.
  
 Section 4.3 Failure or Waiver of Conditions Precedent. In the event any of the conditions set forth in Section 4.1 or 4.2 do not occur as of the Closing Date, or have not been waived in writing by the party for whose benefit the failed condition exists, such party may terminate this Agreement by written notice to the other party, and neither party shall have any further obligation to the other, other than as stated in this Agreement to survive a termination hereof. Buyer and Seller may, at their election, at any time, waive in writing the benefit of any of the conditions set forth in Section 4.1 or 4.2. A party’s waiver of any condition to the Closing shall not constitute a waiver by that party of any other unsatisfied conditions or of such party’s right to terminate this Agreement based on said other unsatisfied conditions, unless such waiver is specified in writing by such party.
  
 ARTICLE 5
 CLOSING
  
 Section 5.1  Closing Deliverables by Buyer. Not later than 2:00 p.m. New York City time on the Closing Date as to (a) below and otherwise not later than the Business Day prior to the Closing Date, Buyer shall deliver to Seller:
  
 (a) the Cash Purchase Price, by means of a wire transfer to Seller of U.S. Dollars in immediately available federal funds;
  
 (b) the Warrant;
  
 (c) counterpart original of the Assignment and Assumption Agreement executed by Buyer;
  
  
 
 
 
 
 
 	 
	8
	

	 

 
 
  
 
 
 
 
 (d) counterpart original of the Notice of Transfer executed by Buyer;
  
 (e) an original Buyer’s Closing Certificate executed by Buyer.
  
 Section 5.2 Closing Deliverables by Seller. Not later than the Business Day prior to the Closing Date, Seller shall deliver to Buyer the following:
  
 (a) counterpart original of the Assignment and Assumption Agreement executed by Seller;
  
 (b) counterpart original of the Notice of Transfer executed by Seller;
  
 (c) an original Seller’s Closing Certificate executed by Seller. Section 5.3 Delivery of Closing Documents and Loan Documents.
  
 (a) Upon Buyer’s receipt of all of the items referenced in Section 5.2 above, Buyer shall wire transfer the Cash Purchase Price to Seller pursuant to instructions previously delivered to Buyer by Seller. Upon receipt by Seller of the Purchase Price and confirmation that Buyer has delivered all documents required to be delivered to Seller pursuant to Section 5.1 above, Seller shall authorize its counsel to deliver to Buyer’s counsel, at the office of Buyer’s counsel the originals (or, if originals are not in the possession or control of Seller, a copy) of all other Loan Documents in Seller’s possession or control.
  
 (b) Subsequent to Closing, Buyer shall have the right, at Buyer’s option and expense, to have items requested by Buyer from the Loan File either delivered to Buyer at the address specified by Buyer or collected by Buyer from the location at which the Loan File is stored; provided that in no event shall Buyer be entitled to receive any Excluded Documents.
  
 Section 5.4  Closing Costs. At Closing, each party shall pay the fees and expenses of its legal counsel incurred in connection with this transaction. Seller shall not bear the cost of any recording fees and/or taxes associated with selling, transferring, and assigning the Loan (including, without limitation, recording any of the Closing Documents and payment of any applicable mortgage tax), all of which costs shall be borne by Buyer (including, without limitation, the reasonable third-party fees and costs incurred by Seller in connection with Seller’s cooperation therewith).
  
 Section 5.5  Prorations. Any collections received by Seller or, its servicer, with respect to the Loan which pursuant to the Loan Documents are payable to Seller or its servicer prior to the Closing Date shall be retained by Seller. Buyer shall be entitled to any such collections received with respect to the Loan on or after the Closing Date. Any and all payments received by a party from or on behalf of any Obligor which belong to the other party shall be held in trust by such receiving party for the benefit of the other party and shall be delivered to such other party within five (5) Business Days after the receipt thereof in the form received.
  
 Section 5.6  Insurance; Casualty Prior to Closing. On the Closing Date, Seller shall have the right to terminate any insurance policies maintained by Seller, if any, with respect to the Collateral. Buyer is responsible for obtaining any insurance it desires to have in effect with respect to the Collateral. Buyer is also responsible for having itself added and/or substituted as loss payee, additional insured, mortgagee or otherwise on any insurance policy relating to the Collateral.
   
  
 
 
 
 
 
 	 
	9
	

	 

 
 
  
 
 
 
 
 Section 5.7  Financing Statements. Effective upon the Closing, Seller authorizes Buyer to prepare and file and/or record, as applicable, assignments of any Uniform Commercial Code financing statements that may be of record with regard to the personal property security interests set forth in the Loan Documents, the Superseded Credit Agreement or in any security agreement which is part of the Loan Documents and/or the Superseded Credit Agreement.
  
 Section 5.8  Reservation of Claims. Notwithstanding any provision of this Agreement, the purchase and sale of the Loan Rights and Obligations shall not include any claims and/or causes of action Seller had, has or may have against any officer, director, employee, insider, accountant, attorney, appraiser, underwriter, broker or other person or entity employed or retained by Seller or any prior owner of the Loan with respect to events occurring prior to the Closing Date. The forgoing is not intended as a limitation on Buyer’s rights to enforce the Loan in accordance with its terms and to realize the benefits of any lien, mortgage or any other security therefor.
  
 Section 5.9  Tax Reporting. On the Closing Date, Seller shall be relieved of, and Buyer shall assume all responsibility for, any tax reporting required with respect to the Loan, including, without limitation, any reporting which may be required with respect to debt forgiveness.
  
 Section 5.10 Survival. The provisions of Section 5.3, Section 5.4 and Sections 5.7 through 5.10 above shall survive the Closing.
  
 ARTICLE 6
 REMEDIES FOR BREACH
  
 Section 6.1  Seller’s Breach. If Seller fails to perform its obligations hereunder to assign and transfer the Loan Rights and Obligations to Buyer on the Closing Date and all of Seller’s Conditions Precedent have been satisfied, Buyer shall be entitled, as its sole and exclusive remedy, either to: (i) terminate this Agreement (in which event this Agreement shall be of no further force or effect except for any obligations which by their express terms survive the termination of this Agreement); or (ii) proceed against Seller by bringing an action, not later than ninety (90) days after the Closing Date, for specific performance hereunder without any right to seek damages of any kind or nature.
  
 Section 6.2 Buyer’s Breach. If Buyer fails to perform its obligations hereunder to purchase and assume the Loan Rights and Obligations from Seller on the Closing Date and all of Buyer’s Conditions Precedent have been satisfied or Buyer is otherwise in default of any of its obligations, representations or warranties hereunder, Seller’s sole and exclusive remedy at law or in equity shall be to terminate this Agreement (in which event this Agreement shall be of no further force or effect except for any obligations which by their express terms survive the termination of this Agreement).
  
  
 
 
 
 
 
 	 
	10
	

	 

 
 
  
 
 
 
 
 Section 6.3  No Personal Liability. In no event shall any direct or indirect shareholder, member, partner, other beneficial owner, director, officer, employee, agent, attorney, consultant, servicer, trustee, or advisor (including any operating advisor) of Seller or of the other Released Parties be personally liable for any obligations of Seller under this Agreement. In no event shall any direct or indirect shareholder, member, partner, other beneficial owner, director, officer, employee, agent, attorney, consultant, or advisor of Buyer be personally liable for any obligations of Buyer under this Agreement. The rights and obligations of the parties hereto under the provisions of this Section 6.3 shall survive any Closing or termination of this Agreement.
  
 ARTICLE 7
 MISCELLANEOUS PROVISIONS
  
 Section 7.1 Notices. Unless otherwise provided for herein, all notices and other communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given (a) two (2) Business Days after being deposited in the U.S. mail, with postage pre-paid, if sent by registered or certified mail (return receipt requested), (b) when delivered, if delivered personally, (c) on the following Business Day after being sent by overnight mail or nationally-recognized overnight courier or (d) in the case of e-mail, upon the sender’s receipt of an acknowledgment from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement) during normal business hours (or, if such acknowledgement is received after normal business hours, on the following Business Day); provided that any delivery via e-mail shall not be deemed effective unless such delivery is followed by delivery via one of the other methods of delivery described herein, in each case to the parties at the following addresses (or at such other addresses as shall be specified by like notice):
  
  
 
 
 	  
	   If to the Buyer:
 
	  
	 The Healing Company Inc. 
 Ten Grand St., 11th Floor 
 Brooklyn, NY 11249 
 Attention: Simon Belsham
 E-mail: Simon@healingcompany.com

	  
	  
	  
	  

	  
	   With a copy to:
 
	  
	 Bevilacqua PLLC
 1050 Connecticut Ave., NW, Suite 500
 Washington, DC 20036 
 Attention: Lou Bevilacqua
 E-mail: lou@bevilacquapllc.com

	  
	  
	  
	  

	  
	   If to Seller:
 
	  
	 CircleUp Credit Advisors LLC 
 548 Market Street PMB 60874 
 San Francisco, CA 94104 
 Attention:
  
E-mail:

	  
	  
	  
	  

	  
	   With a copy to:
 
	  
	 Loeb & Loeb LLP 
 345 Park Avenue
 New York, NY 10154

	  
	  
	  
	  

	  
	  
	  
	 Attention: Scott J. Giordano 
 E-mail: sgiordano@loeb.com

 

  
 
 
 
  
 
 
 
 
 
 	 
	11
	

	 

 
 
  
 
 
 
 
 The provisions of this Section 7.1 shall survive the Closing.
  
 Section 7.2  Severability. Each part of this Agreement is intended to be severable. If any term, covenant, condition or provision hereof is unlawful, invalid, or unenforceable for any reason whatsoever, and such illegality, invalidity, or unenforceability does not affect the remaining parts of this Agreement, then all such remaining parts hereof shall be valid and enforceable and have full force and effect as if the invalid or unenforceable part had not been included.
  
 Section 7.3 Rights Cumulative; Waivers. The rights of each of the parties under this Agreement are cumulative and may be exercised as often as any party considers appropriate. The right of each of the parties hereunder shall not be waived or varied other than by an express waiver or variation in writing. Any failure to exercise or any delay in exercising any of such rights shall not operate as a waiver or variation of that or any other such right. Any defective or partial exercise of any of such rights shall not preclude any other or further exercise of that or any other such right. No act or course of conduct or negotiation on the part of any party shall in any way preclude such party from exercising any such right or constitute suspension or any variation of any such right.
  
 Section 7.4 Headings. The headings of the Articles and Sections contained in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provision hereof.
  
 Section 7.5 Construction. Unless the context otherwise requires, singular nouns and pronouns, when used herein, shall be deemed to include the plural of such noun or pronoun and pronoun of one gender shall be deemed to include the equivalent pronoun of the other gender.
  
 Section 7.6 Assignments; Third Party Beneficiaries. This Agreement may not be assigned by Buyer without the prior written consent of Seller, which consent may not be unreasonably withheld; provided, however, that no such assignment shall relieve Buyer from any of its obligations hereunder or delay the Closing of this transaction. Any attempted assignment by Buyer without the prior written consent of Seller shall be voidable by Seller; provided, however, upon not less than ten (10) Business Days prior written notice to Seller, Buyer may designate an affiliate of Buyer to take title to and assume the Loan Rights and Obligations, provided Buyer has provided all information with respect to such affiliate requested by Seller to perform Seller’s due diligence and Seller’s diligence regarding such affiliate has not revealed any information regarding such affiliate or its principals, officers, directors, or direct or indirect owners that would make it undesirable, in Seller’s sole determination, for Seller to consummate the transactions contemplated by this Agreement, which affiliate shall execute the applicable Closing Documents and be deemed to have made each and every representation and warranty of Buyer in this Agreement as to itself, and which affiliate shall be deemed to be bound by and shall perform all of the obligations of Buyer under this Agreement, on a joint and several basis. Subject to the foregoing, this Agreement and the terms, covenants, conditions, provisions, obligations, undertakings, rights and benefits hereof, including the Exhibits hereto, shall be binding upon and shall inure to the benefit of, the undersigned parties and their respective successors, and assigns. Except for those provisions benefitting the Released Parties, nothing expressed or mentioned in this Agreement is intended or will be construed to give any other Person any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of Seller and Buyer and for the benefit of no other Person.
  
  
 
 
 
 
 
 	 
	12
	

	 

 
 
  
 
 
 
 
 Section 7.7 Entire Agreement. This Agreement supersedes any and all prior discussions and agreements between Seller and Buyer with respect to the purchase of the Loan and other matters contained herein, and this Agreement contains the sole and entire understanding between the parties hereto with respect to the transactions contemplated herein. This Agreement is the product of negotiation between Seller and Buyer. No party is deemed the drafter of this Agreement.
  
 Section 7.8  Modifications. This Agreement shall not be altered or modified except by a subsequent writing, signed by Buyer and Seller.
  
 Section 7.9 Counterparts. This Agreement may be executed in .pdf format and delivered by email and in any number of counterparts, each of which shall constitute one and the same instrument, and either party hereto may execute this Agreement by signing any such counterpart.
  
 Section 7.10 Survival. Except as and to the extent expressly provided otherwise in this Agreement, terms, conditions, and provisions of this Agreement, and any representations and/or warranties contained in this Agreement, shall not survive the Closing and shall instead merge into the Closing Documents.
  
 Section 7.11 Governing Law; Venue; Waiver of Jury Trial.
  
 (a) THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAWS WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
  
 (b) THE PARTIES HERETO AGREE TO SUBMIT TO PERSONAL JURISDICTION IN THE STATE OF NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF THIS AGREEMENT AND, IN FURTHERANCE OF SUCH AGREEMENT, THE PARTIES HEREBY AGREE AND CONSENT THAT, WITHOUT LIMITING OTHER METHODS OF OBTAINING JURISDICTION, PERSONAL JURISDICTION OVER THE PARTIES IN ANY SUCH ACTION OR PROCEEDING MAY BE OBTAINED WITHIN OR WITHOUT THE JURISDICTION OF ANY COURT LOCATED IN NEW YORK, NEW YORK. EACH PARTY HERETO HEREBY EXPRESSLY WAIVES ANY AND ALL RIGHTS THAT IT MAY HAVE TO MAKE ANY OBJECTIONS BASED ON JURISDICTION OR VENUE TO ANY ACTION BROUGHT TO ENFORCE THIS AGREEMENT IN ANY SUCH COURT IN ACCORDANCE WITH THE ABOVE PROVISIONS. THE PROVISIONS OF THIS SECTION 7.11 SHALL SURVIVE THE CLOSING.
  
  
 
 
 
 
 
 	 
	13
	

	 

 
 
  
 
 
 
 
 Section 7.12 Publicity; Litigation; Confidentiality. In no event shall Buyer (a) issue any press release, publicity, advertising, promotion, or otherwise announce or disclose or cause or permit to be announced or disclosed in any manner whatsoever this Agreement or the transaction contemplated hereby or otherwise disclose the terms and conditions of this Agreement, (b) institute or continue any legal action in the name of Seller or any other Released Party, (c) intentionally or unintentionally, through misrepresentation or nondisclosure, conceal or mislead any person as to Buyer’s identity, or (d) use or refer to Seller’s or any other Released Party’s name or any name derived from Seller’s or any other Released Party’s name to promote the sale or transfer of the Loan or the collection or management of the Loan (provided that in descriptions of the Loan, Buyer may refer to the Loan as having been previously held by Seller and that Buyer is Seller’s successor-in-interest to the Loan), in each case without the prior written consent of Seller, which consent will not be unreasonably withheld. Furthermore, Buyer agrees to keep all aspects of the transaction contemplated by this Agreement and all materials and information provided to Buyer in connection with the transaction contemplated hereby (including, without limitation, this Agreement, the Loan Documents and the Loan File, other than information that is or becomes publicly-available through no action of Buyer or any agent of Buyer (collectively, “Confidential Information”)), strictly confidential and not disclose the same to any persons; provided, however, that nothing herein shall be deemed to limit or impair in any way Buyer’s ability to disclose the details of the transaction contemplated hereby to its legal and financial advisors, investors, partners, or lenders or as may be necessary pursuant to any court or governmental order or applicable law, including any REIT or SEC filing, disclosure or reporting requirements, or in bankruptcy proceeding or litigation; provided, further, that Buyer shall inform such parties of the confidential nature of the Confidential Information and shall be responsible for a breach of this Agreement caused by such parties; and provided, further, that subsequent to Closing Buyer shall not be obligated to treat as confidential the Loan Documents, the Loan File and materials derived therefrom. In the event that Buyer or such parties become legally compelled to disclose all or any part of such Confidential Information under a subpoena or inquiry issued by a court of competent jurisdiction or by a judicial or administrative agency, Buyer shall immediately provide Seller with prompt notice so that Seller may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Section and shall consult with Seller on the advisability of taking legally available steps to resist or narrow such request and cooperate with the Seller on any steps it considers advisable. In the event that such protective order or other remedy is not obtained, or that Seller waives compliance with the provisions of this Section, Buyer will furnish only that portion of the Confidential Information which is legally required. The rights and obligations of the parties hereto under the provisions of this Section 7.12 shall survive any Closing or termination of this Agreement.
  
 Section 7.13 Brokers. Each party to this Agreement represents and warrants to the other that, in connection with the sale and purchase of the Loan, the party so representing and warranting has not dealt with any real estate broker, agent or finder. Buyer and Seller shall indemnify and hold each other harmless against and from any and all actual out-of-pocket losses, actual damages (expressly excluding special, consequential, punitive and exemplary damages), costs and expenses (including, without limitation reasonable attorneys’ fees) arising as a result of any breach of the foregoing representation and warranty. The rights, obligations, warranties and representations of the parties hereto under the provisions of this Section 7.13 survive any closing or termination of this Agreement.
   
  
 
 
 
 
 
 	 
	14
	

	 

 
 
  
 
 
 
 
 Section 7.14 Effectiveness of the Agreement. This Agreement shall not be deemed a contract binding upon Seller unless and until Seller shall have executed this Agreement and Buyer shall have delivered the Cash Purchase Price to Seller in accordance with the terms and conditions of this Agreement.
  
 Section 7.15 Further Assurances. From and after the date of this Agreement, each party shall execute and deliver such other documents and items, and take such other actions, as may be reasonably requested by the other party to allow the completion and consummation (or termination, as appropriate) of all tasks and the transactions contemplated by this Agreement. The provisions of this Section 7.15 shall survive the Closing.
  
 Section 7.16 Time of Essence. All parties hereto agree that time is of the essence with respect to this Agreement.
  
 [SIGNATURE PAGE FOLLOWS]
  
  
 
 
 
 
 
 	 
	15
	

	 

 
 
  
 
 
 
 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first above written.
  
  
 
 
 
 
 
 	 	 SELLER:
	
	  
	  
	  

	  
	 CIRCLEUP CREDIT ADVISORS LLC
	  

	 	 	 	 
		By:	/s/ Nicholas Brown	
	  
	 Name:
	 Nicholas Brown
	 
	 	Title:	 President
	 
	 	 	 	 
	  
	 BUYER:
	  

	  
	  
	  

	  
	 THE HEALING COMPANY INC.
	  

	  
	   
	  

	  
	 By:
	 /s/ Simon Belsham
	  

	  
	 Name:
	 Simon Belsham
	  

	  
	 Title: 
	 CEO
	  

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 SIGNATURE PAGE TO
 LOAN PURCHASE AND SALE AGREEMENT
  
  
 
 
 
 
 
 	 
	16
	

	 

 
 
  
 
 
 
 
 SCHEDULE 1
  
 DEFINITIONS
  
 For purposes of this Agreement, the following terms shall have the follow respective meanings:
  
 “Account Debtor” means the Person or entity obligated on a trade account, account receivable, other receivable, or other right to payment for goods sold or services rendered owing to Borrower.
  
 “Agreement” means this Agreement as defined in the recitals hereto, including all Exhibits and Schedules hereto, as all of the foregoing may be amended, restated, modified, replaced, supplemented, renewed, extended or otherwise modified from time to time.
  
 “Assignment and Assumption Agreement” means the Assignment and Assumption Agreement in the form attached hereto as Exhibit B.
  
 “Borrower” means individually and collectively Your Superfoods, Inc. and Your Super, Inc.
  
 “Business Day” means any day on which banks in New York, New York, are open for business, other than a Saturday, a Sunday or a New York or Federal holiday.
  
 “Buyer’s Closing Certificate” means the Buyer’s Closing Certificate in the form attached hereto as Exhibit D.
  
 “Buyer’s Closing Documents” means all documents executed by Buyer in connection with this Agreement and the transactions contemplated hereunder.
  
 “Buyer’s Conditions Precedent” has the meaning set forth in Section 4.1.
  
 “Cash Purchase Price” means the sum of Two Million and No/100 Dollars ($2,000,000.00).
  
 “Claims” has the meaning set forth in Section 2.7.
  
 “Closing” means the consummation of the transaction contemplated in this Agreement (including Seller’s receipt of the Cash Purchase Price and the Warrant).
  
 “Closing Date” means 09, 2022, or such other date upon which Buyer and Seller may mutually agree in writing.
  
 “Closing Documents” means all documents described herein that are required to be delivered at the Closing by Seller or Buyer pursuant to this Agreement.
  
  
 
 
 
 
 
 	 
	17
	

	 

 
 
  
 
 
 
 
 “Collateral” means all of Borrower’s properties and assets (real and personal) and rights against Account Debtors, in each case, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof, including without limitation all goods (including inventory, equipment and any accessions thereto), fixtures, instruments (including promissory notes), documents, accounts (including health-care-insurance receivables), chattel paper (whether tangible or electronic), deposit accounts, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), books and records, commercial tort claims, securities and all other investment property, supporting obligations, any other contract rights or rights to the payment of money, all money, cash and cash equivalents, insurance claims and proceeds, and all general intangibles (including all payment intangibles).
  
 “Confidential Information” has the meaning set forth in Section 7.12. “Control” or “Controlled” has the meaning set forth in Section 2.3.
  
 “Effective Date” has the meaning set forth in the introductory paragraph to this Agreement.
  
 “Excluded Documents” means any and all of the following: (a) documents and files related to Seller’s acquisition of the Loan (other than the documents actually assigning the Loan and Loan Documents to Seller and the Loan Documents); (b) e-mail correspondence to or from any Obligor, counsel to any Obligor, Seller and/or Seller’s attorneys, advisors, and consultants;
 (c)     documents or materials that are confidential, subject to non-disclosure requirements, attorney/client privileged, relate to Seller’s strategies or plans for the Loan, or not relevant to the analysis by Buyer of the Loan, such as (but not limited to) regulatory reports, memoranda, summaries, notes, analyses, and correspondence between the Seller and its counsel, servicers, operating advisors, and other advisors and consultants; (d) written or electronic correspondence which is not related to the Loan; (e) proprietary information; (f) duplicates, drafts and unexecuted documents; (g) documents and information that are publicly-available; (h) documents and materials that are the property of any of Seller’s counsel, servicers, operating advisors, and other advisors and consultants; and (i) all other documents, instruments, and materials which are not in the possession or control of Seller. For purposes of this definition, the term “Seller” also includes all of the Released Parties.
  
 “Lender” means CircleUp Credit Advisors LLC, a Delaware limited liability company, its successors and assigns.
  
 “Loan” means collectively any and all loans and financial accommodations from Lender to Borrower described in the Loan Agreement or described on any exhibit or schedule attached to the Loan Agreement from time to time, and further including any and all subsequent amendments, additions, substitutions, renewals and refinancings of any of the Loans.
  
 “Loan Agreement” means the Amended and Restated Credit and Security Agreement dated April 13, 2022 by and among Borrowers and Seller.
  
 “Loan Documents” means all agreements and documents evidencing or securing the Loan, including, without limitation, the Loan Agreement and the Loan File and any and all amendments thereto and the documents listed on Exhibit A.
  
  
 
 
 
 
 
 	 
	18
	

	 

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 “Loan File” means all material written records, notices, correspondence, third-party reports, operating statements, rent rolls, surveys, title policies, insurance policies and certificates and other documents and materials relating to the Loan that are in the possession or control of Seller, other than the Excluded Documents.
  
 “Loan Rights and Obligations” means any and all of Seller’s right, title, interest and obligations in, to, under, and with respect to the Loan, the Loan Documents, the Collateral and the Loan File.
  
 “Notice of Transfer” means the Notice of Transfer in the form attached hereto as Exhibit C.
  
 “Obligations” has the meaning set forth in the Loan Agreement.
  
 “Obligor” means any Person named as borrower, mortgagor, debtor, guarantor, indemnitor, or similar capacity under any of the Loan Documents.
  
 “OFAC” has the meaning set forth in Section 2.3.
  
 “Patriot Act” means the USA Patriot Act of 2001, 107 Public Law 56 (October 26, 2001) (together with all other statutes and all orders, rules and regulations of the United States government and its various executive departments, agencies and offices related to the subject matter of the Patriot Act, including Executive Order 13224 effective September 24, 2001), as the same may be amended from time to time.
  
 “Person” means and includes natural persons, corporations, limited liability companies, limited liability partnerships, limited partnerships, general partnerships, joint stock companies, joint ventures, associations, companies, trusts, banks, trust companies, land trusts, business trusts, real estate investment trusts or other organizations, whether or not legal entities, and governments, agencies and countries and political subdivisions thereof.
  
 “Purchase Price” means the Cash Purchase Price and the Warrant. “Prohibited Person” has the meaning set forth in Section 2.3. “Released Matters” has the meaning set forth in Section 2.6. “Released Parties” has the meaning set forth in Section 2.6. “Releasing Parties” has the meaning set forth in Section 2.6.
  
 “Seller Indemnified Parties” has the meaning set forth in Section 2.7.
  
 “Seller’s Closing Certificate” means the Seller’s Closing Certificate in the form attached hereto as Exhibit E.
  
 “Seller’s Conditions Precedent” has the meaning set forth in Section 4.2. “Seller’s Representations” has the meaning set forth in Section 2.4.
  
 “Superseded Credit Agreement” means that certain Credit and Security Agreement dated as of December 20th, 2019 (as amended, modified, restated or supplemented from time to time) by and between Seller and Borrower.
  
 “Warrant” means the Common Stock Purchase Warrant issued by The Healing Company Inc. (“Issuer”) to Seller on the Closing Date to purchase up to 1,500,000 fully-paid and nonassessable shares of the Issuer’s common stock, $0.001 par value per share, at an exercise price of $2.00 per share, in the form attached hereto as Exhibit G.
  
  
 
 
 
 
 
 	 
	19
	

	 

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 EXHIBIT A 
  
 LOAN DOCUMENTS
  
 1. Amended and Restated Credit and Security Agreement dated April 13, 2022 by and among Your Superfoods, Inc. and Your Super, Inc., as Borrowers, and CircleUp Credit Advisors LLC, as Lender, as amended by Joinder, Amendment and Forbearance Agreement dated as of September 2, 2022 by and among Borrowers and Lender.
  
 2. Lender Approval effective as of July 14, 2021 by CircleUp Credit Advisors LLC for the benefit of your Superfoods, Inc. relating to a Convertible Promissory Note in the original principal amount of $2,000,000 made by Your Super, Inc. in favor of Siddhi Capital Fund, I, L.P.
  
  
 
 
 
 
 
 	 
	20
	

	 

 
 
  
 
 
 
 
 EXHIBIT B
  
 FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT
  
 ASSIGNMENT AND ASSUMPTION AGREEMENT
  
 This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment”) is entered into by and between CIRCLEUP CREDIT ADVISORS LLC (“Assignor”) and THE HEALING COMPANY INC, a Nevada Corporation (“Assignee”).
  
 RECITALS
  
 A. Assignor and Assignee entered into that certain Loan Purchase and Sale Agreement dated and effective 09/09, 2022 (the “Agreement”).
  
  
 B. The Agreement provides for the sale and transfer by Assignor to Assignee of certain Loan Rights and Obligations (such term and all other capitalized terms used herein and not otherwise defined herein have the definitions ascribed to them in the Agreement).
  
 NOW, THEREFORE, in consideration of the foregoing premises and mutual agreements herein contained, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee agree as follows:
  
 1. Assignor hereby transfers, assigns and conveys all of Assignor’s right, title, interest and obligations in, to and under the Loan Rights and Obligations. THIS SALE AND ASSIGNMENT IS MADE ON AN “AS-IS,” “WHERE-IS” BASIS, “WITH ALL FAULTS” AND WITHOUT REPRESENTATIONS, EXPRESS OR IMPLIED, OF ANY TYPE, KIND, CHARACTER OR NATURE, EXCEPT THE EXPRESS REPRESENTATIONS OF SELLER SET FORTH IN ARTICLE 3 OF THE AGREEMENT.
  
 2. Assignee hereby assumes any and all of the Assignor’s liabilities, duties and obligations under or with respect to the Loan Rights and Obligations, in each case to the extent arising or accruing on or after the Closing Date.
  
 3. This Assignment may be executed in counterparts.
  
 4. This Assignment shall, and the rights and obligations of the parties hereunder shall be, construed in accordance with the laws of the State of New York applicable to contracts negotiated, made and to be performed entirely within such state.
  
 5. This Assignment shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns.
  
 [The remainder of this page is intentionally blank.]
  
  
 
 
 
 
 
 	 
	21
	

	 

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 IN WITNESS WHEREOF, the parties hereto have executed this Assignment to be effective as of the date first above written.
  
  
 
 
 
 
 
 	 	 ASSIGNOR:
	
	  
	  
	  

	  
	 CIRCLEUP CREDIT ADVISORS LLC
	  

	 	 	 	 
		By:	/s/ Nicholas Brown	
	  
	 Name:
	 Nicholas Brown
	 
	 	Title:	 President
	 
	 	 	 	 
	  
	 ASSIGNEE: 
	  

	  
	  
	  
	  

	  
	 THE HEALING COMPANY INC.
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Simon Belsham
	  

	  
	 Name: 
	 Simon Belsham
	  

	  
	 Title:
	 CEO
	  

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 	 
	22
	

	 

 
 
  
 
 
 
 
 
 
 
 
 
 
   
 EXHIBIT C
  
 FORM OF NOTICE OF TRANSFER
  
 NOTICE OF TRANSFER
   
  
 
 
 
 
 
 		 09/09                              ,2022

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 	  
	  

	  
	  

	  
	  

 
 
  
 
 
 
 
  
 
 
 
 
 
 	  
	 Re:
	 Debt of Your Super                              (the “Loan”)

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 Ladies and Gentlemen:
  
 Notice is hereby given that CIRCLEUP CREDIT ADVISORS LLC (“Lender”), the current holder of the above-described Loan, has transferred 100% of its interest in the Loan to THE HEALING COMPANY INC., a Nevada corporation (“Transferee”), effective as of the date written above, and Transferee has assumed Lender’s obligations with respect thereto arising only from and after the date written above. Contact information for the above-named Transferee is as follows:
  
  
 
 
 	  
	   Attention: 
	  
	 Simon Belsham

	  
	   Facsimile No.:
	  
	 n/a

	  
	  
	  
	  

	   Any future payments in respect of the Loan should be sent to the following account:

	  
	  
	  
	  

	  
	   Bank: 
	  
	 First Republic Bank

	  
	   ABA No.:
	  
	 321081669

	  
	   Account No.:
	  
	  

	  
	   Name:
	  
	 The Healing Company Inc

	  
	   Reference:
	  
	 YourSuper Simon 

	  
	   Contact:
	  
	 Belsham

 
 
  
 
 
  
  
As required under the documents evidencing and securing the Loan, Transferee must be named as an additional insured, mortgagee and/or loss payee under all applicable insurance and evidence of such amendments should be sent to Transferee at its address specified above.
  
  
 
 
 
 
 
 	 
	23
	

	 

 
 
  
 
 
 
 
 Executed to be effective as of the date first written above.
  
  
 
 
 
 
 
 	  
	  
	  

	  
	 CIRCLEUP CREDIT ADVISORS LLC
	  

	 	 	 	 
		By:	/s/ Nicholas Brown	
	  
	 Name:
	 Nicholas Brown
	 
	 	Title:	 President
	 
	 	 	 	 
	  
	 THE HEALING COMPANY INC.
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Simon Belsham
	  

	  
	 Name: 
	 Simon Belsham
	  

	  
	 Title:
	 CEO
	  

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	24
	

	 

 
 
  
 
 
 
 
 EXHIBIT D
  
 FORM OF BUYER’S CLOSING CERTIFICATE
  
 BUYER’S CLOSING CERTIFICATE
  
 This Buyer’s Closing Certificate is being delivered by the undersigned pursuant to Section 5.1 of that certain Loan Purchase and Sale Agreement dated as of 9th September                          ,
 2022 (the “Agreement”) among CIRCLEUP CREDIT ADVISORS LLC (“Seller”), and THE HEALING COMPANY INC. (“Buyer”).
  
 The undersigned hereby certifies to Seller that the each of the representations and warranties made by Buyer in the Agreement are true and correct in all material respects as to the undersigned on and as of the date hereof with the same force and effect as if made by the undersigned on the date hereof.
  
  
 
 
 
 
 
 	 	 BUYER:
	
	  
	  
	  

	  
	 THE HEALING COMPANY INC.
	  

	 	 	 	 
		By:	/s/ Simon Belsham	
	  
	 Name: 
	Simon Belsham	 
	 	Title: 	 CEO
	 

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	25
	

	 

 
 
  
 
 
 
 
 EXHIBIT E
  
 FORM OF SELLER’S CLOSING CERTIFICATE 
  
 SELLER’S CLOSING CERTIFICATE
  
 This Seller’s Closing Certificate is being delivered by the undersigned pursuant to Section 5.2 of that certain Loan Purchase and Sale Agreement dated as of 09/09                                         ,
 2022 (the “Agreement”) among CIRCLEUP CREDIT ADVISORS LLC (“Seller”), and THE HEALING COMPANY INC. (“Buyer”).
  
 The undersigned hereby certifies to Buyer that the each of the representations and warranties made by Seller in Article 3 of the Agreement are true and correct in all material respects as to the undersigned on and as of the date hereof with the same force and effect as if made by the undersigned on the date hereof.
  
  
 
 
 
 
 
 	 	 SELLER:
	
	  
	  
	  

	  
	 CIRCLEUP CREDIT ADVISORS LLC
	  

	 	 	 	 
		By:	/s/ Nicholas Brown	
	  
	 Name:
	Nicholas Brown	 
	 	Title:	 President
	 

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	26
	

	 

 
 
  
 
 
 
 
 EXHIBIT F
  
 SELLER’S WIRE TRANSFER INSTRUCTIONS
  
  
 
 
 
 
 
 	 
	27
	

	 

 
 
  
 
 
 
 
 EXHIBIT G
  
 Form of Warrant
  
  
 
 
 
 
 
 	 
	28
	

	 

 
 
  
 
 
 
 
 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
  
 COMMON STOCK PURCHASE WARRANT 
 THE HEALING COMPANY INC.
  
  
 
 
 
 
 
 	 Warrant Shares: 1,500,000
	  
	 Initial Issue Date: __________09/09, 2022

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for good and valuable consideration, the receipt of which is hereby acknowledged, CircleUp Credit Advisors LLC (“Holder”) is entitled to purchase, subject to the terms and conditions of this Warrant, from The Healing Company Inc., a Nevada corporation (the “Company”), up to 1,500,000 fully-paid and nonassessable shares (the “Shares”) of the Company’s Common Stock at a price per share as set forth below. This Warrant is being issued to the Holder in connection with that certain Loan Purchase and Sale Agreement (the “Agreement”) by and between the Company and the Holder. Holder shall be entitled to purchase the Shares in accordance with Section 2 and the vesting schedule set forth in Section 1.2 and prior to the Expiration Date (as defined below). The Shares of the Company or the Issuer are subject to adjustment from time to time pursuant to the terms hereof. Capitalized terms used, but not defined, herein have the respective meanings ascribed to them in the Agreement.
  
 1. Exercise Period; Exercise of Warrant.
  
 1.1 Exercise Period. This Warrant shall terminate at 5:00 p.m. Eastern Time on September 5th, 20291 (the “Expiration Date”).
  
 1.2 Exercise. This Warrant shall begin to vest on the one-year anniversary of the Closing with 12.5% of the Warrant amount (187,500 shares) vesting on that date and the remaining portion of the Warrant vesting in seven quarterly installments of 187,500 shares each over the next seven quarters. Vesting of the Warrant will be accelerated upon the occurrence of a sale or merger of the Company in a transaction involving a third party.
  
 1 Insert date that is seventh anniversary of Initial Issue Date.
  
  
 
 
 
 
 
 	 
	29
	

	 

 
 
  
 
 
 
 
 1.3 Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $2.00, subject to adjustment hereunder (the “Exercise Price”).
  
 2. Exercise Procedure; Payment; Forced Exercise.
  
 2.1 Cash Exercise. At any time after the date of this Warrant and in accordance with the vesting schedule set forth in Section 1.2, this Warrant may be exercised from time to time by Holder, during the term hereof, by surrender of this Warrant and the Notice of Exercise attached hereto, duly completed and executed by Holder, to the Company at the principal corporate offices of the Company, together with payment in the amount obtained by multiplying the Exercise Price then in effect by the number of Shares thereby purchased, as designated in the Notice of Exercise. Payment may be in cash or by check payable to the order of the Company.
  
 2.2 Net Issuance. In lieu of payment of the Exercise Price described in Section 1.3, Holder may elect to receive, without the payment by Holder of any additional consideration, Shares equal to the value of this Warrant or any portion hereof, by the surrender of this Warrant or such portion to the Company, with the net issue election notice attached hereto (the “Net Issuance Election”) duly executed, at the principal executive offices of the Company. Thereupon, the Company shall issue to Holder such number of fully paid and nonassessable Shares as is computed using the following formula:
  
  
 
 
 
 
 
 	  
	 where:
	 X = Y (A-B) 
	  

	  
	  
	 A
	  

 
 
  
 
 
 
 
 X = the number of Shares to be issued to Holder pursuant to this Section 2.
  
 Y = the number of Shares covered by this Warrant in respect of which the net issuance election is made pursuant to this Section 2.
  
 A = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to this Section 2.2 on a day that is not a Trading Day or (2) both executed and delivered pursuant to this Section 2.2 on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(77) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to this Section 2.2 or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to this Section 2.2 after the close of “regular trading hours” on such Trading Day.
  
  
 
 
 
 
 
 	 
	30
	

	 

 
 
  
 
 
 
 
 B = the Exercise Price in effect under this Warrant at the time the net issuance election is made pursuant to this Section 2.
  
 “Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of a share of Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average per share price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on the Pink tier of the OTC Markets (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
  
 “Trading Day” means a day on which the Common Stock is traded on a Trading Market.
  
 “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price per share of Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for Common Stock is then reported on the Pink tier of the OTC Markets (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
  
 If Shares are issued on such a net issuance basis, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), the Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.
  
 3. Reservation of Shares. The Company hereby agrees that at all times there shall be reserved for issuance and delivery upon exercise of this Warrant a sufficient number of shares of its Common Stock to provide for the exercise in full of this Warrant. All such shares shall be duly authorized, and when issued upon such exercise, shall be validly issued, fully paid and non- assessable, free and clear of all liens, security interests, charges and other encumbrances or restrictions on sale and free and clear of all preemptive rights.
  
  
 
 
 
 
 
 	 
	31
	

	 

 
 
  
 
 
 
 
 4. Delivery of Stock Certificates. Within a reasonable time after exercise, in whole or in part, of this Warrant, and payment of the Exercise Price if applicable, the Company shall issue in the name of and deliver to Holder a certificate or certificates for the number of fully paid and nonassessable Shares which Holder shall have requested in the Notice of Exercise or Net Issuance Election, as applicable. If this Warrant is exercised in part, the Company shall deliver to Holder a new Warrant (dated as of the date hereof and of like tenor) for the unexercised portion of this Warrant at the time of delivery of such stock certificate or certificates.
  
 5. No Fractional Shares. No fractional shares or scrip representing fractional shares will be issued upon exercise of this Warrant. If upon any exercise of this Warrant a fraction of a share results, the Company will pay Holder the difference between the cash value of the fractional share and the portion of the Exercise Price allocable to the fractional share.
  
 6. Charges, Taxes and Expenses. The Company shall pay all transfer taxes or other incidental charges, if any, in connection with the transfer of the Shares purchased pursuant to the exercise hereof from the Company to Holder.
  
 7. Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to the Company, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor and dated as of such cancellation, in lieu of this Warrant.
  
 8. Saturdays, Sundays, Holidays, Etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding weekday which is not a legal holiday.
  
 9. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of and kind of securities purchasable upon exercise of this Warrant shall be subject to adjustment from time to time as follows:
  
 9.1 Subdivisions, Combinations, Dividends and Other Issuances. If the Company shall at any time after the date hereof but prior to the expiration of this Warrant subdivide its outstanding securities as to which purchase rights under this Warrant exist, by split-up or otherwise, combine its outstanding securities as to which purchase rights under this Warrant exist, or pay a dividend in shares or a distribution in shares, the number of Shares as to which this Warrant is exercisable as of the date of such subdivision, split-up, combination or dividend shall forthwith be proportionately increased in the case of a subdivision, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant as of such date shall remain the same.
  
  
 
 
 
 
 
 	 
	32
	

	 

 
 
  
 
 
 
 
 9.2 Effect of Consolidation, Merger or Sale. In case of any reclassification, capital reorganization, or change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of any subdivision, combination or stock dividend provided for in Sections 9.1), or in case of any consolidation or merger of the Company with or into any corporation (other than a consolidation or merger with another corporation in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the holder of this Warrant a new warrant (in form and substance satisfactory to the holder of this Warrant), or the Company shall make appropriate provision without the issuance of a new warrant, so that the holder of this Warrant shall have the right to receive, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the Shares theretofore issuable upon exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, capital reorganization, change, merger or sale by a holder of the number of Shares then purchasable under this Warrant. In any such case, appropriate provisions shall be made with respect to the rights and interest of Holder so that the provisions hereof shall thereafter be applicable to any shares of stock or other securities and property deliverable upon exercise hereof, or to any new Warrant delivered pursuant to this Section 9.2, and appropriate adjustments shall be made to the Exercise Price per share payable hereunder, provided, that the aggregate Exercise Price shall remain the same. The provisions of this Section 9.2 shall similarly apply to successive reclassifications, capital reorganizations, changes, mergers and transfers.
  
 10. Notice of Adjustments; Notices. Whenever the Exercise Price or number of Shares purchasable hereunder shall be adjusted pursuant to Section 9 hereof, the Company shall execute and deliver to Holder a certificate setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated and the Exercise Price and number of and kind of securities purchasable hereunder after giving effect to such adjustment, and shall cause a copy of such certificate to be mailed (by first class mail, postage prepaid) to Holder.
  
 11. Rights As Shareholder. Nothing contained in this Warrant shall be construed as conferring upon Holder or Holder’s transferees the right to vote or to receive dividends or to consent or to receive notice as a shareholder in respect of any meeting of shareholders for the election of directors of the Company or of any other matter, or any rights whatsoever as shareholders of the Company.
  
 12. Restricted Securities. The Holder understands that this Warrant and the Shares purchasable hereunder constitute “restricted securities” under the federal securities laws inasmuch as they are, or will be, acquired from the Company in transactions not involving a public offering and accordingly may not, under such laws and applicable regulations, be resold or transferred without registration under the Securities Act, or an applicable exemption from such registration. The Holder further acknowledges that a securities legend to the foregoing effect shall be placed on any Shares issued to Holder upon exercise of this Warrant; provided that no legend will be placed on any Shares issued to Holder pursuant to Section 2.2 if Rule 144(b) is available for the resale of such Shares.
  
  
 
 
 
 
 
 	 
	33
	

	 

 
 
  
 
 
 
 
 13. Transferability. This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form of assignment (the “Assignment Notice”) attached hereto duly executed by the Holder or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of the transferred Warrant under the Securities Act. Upon such surrender, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such Assignment Notice and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
  
 14. Miscellaneous.
  
 14.1 Binding Effect. This Warrant and the various rights and obligations arising hereunder shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
  
 14.2 Entire Agreement. This Warrant and the Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements, whether oral or written, between the parties hereto with respect to the subject matter hereof.
  
 14.3 Amendment and Waiver. Any term of this Warrant may be amended and the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Holder.
  
 14.4 Governing Law. This Warrant shall be governed by and construed under the laws of the State of Nevada without reference to the conflicts of law principles thereof. Any action brought by either party against the other concerning the transactions contemplated by this Warrant shall be brought only in the state courts of New York or in the federal courts located in New York County, in the State of New York. The Company and Holder each irrevocably submits to and accepts, with respect to any such action or proceeding, generally and unconditionally, the jurisdiction of the aforesaid courts, and irrevocably waives any and all rights such party may now or hereafter have to object to such jurisdiction.
  
  
 
 
 
 
 
 	 
	34
	

	 

 
 
  
 
 
 
 
 14.5 WAIVER OF RIGHT TO TRIAL BY JURY. EACH PARTY TO THIS WARRANT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (1) ARISING UNDER THIS WARRANT, THE OTHER TRANSACTION DOCUMENTS, OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION THEREWITH, OR (2) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS WARRANT OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS RELATED HERETO OR THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY. THE PARTIES HERETO HEREBY AGREE THAT THE PROVISIONS CONTAINED HEREIN HAVE BEEN FAIRLY NEGOTIATED ON AN ARM’S-LENGTH BASIS, WITH BOTH SIDES AGREEING TO THE SAME KNOWINGLY AND BEING AFFORDED THE OPPORTUNITY TO HAVE THEIR RESPECTIVE LEGAL COUNSEL CONSENT TO THE MATTERS CONTAINED HEREIN. ANY PARTY TO THIS WARRANT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY AND THE AGREEMENTS CONTAINED HEREIN REGARDING THE APPLICATION OF JUDICIAL REFERENCE IN THE EVENT OF THE INVALIDITY OF SUCH JURY TRIAL WAIVER.
  
 14.6 Headings. The headings in this Warrant are for convenience only and shall not alter or otherwise affect the meaning hereof.
  
 14.7 Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and the balance shall be enforceable in accordance with its terms.
  
 14.8 Counterparts. This Note may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
  
 14.9 Notices. Unless otherwise provided, any notice required or permitted under this Warrant shall be given in the same manner as provided in the Subscription Agreement.
  
 [Signature Page Follows]
  
  
 
 
 
 
 
 	 
	35
	

	 

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Warrant as of the date appearing on the first page of this Warrant.
  
  
 
 
 
 
 
 	 	THE COMPANY:	
	  
	  
	  

	  
	 THE HEALING COMPANY INC.
	  

	 	 	 	 
	  
	  
	 /s/ Simon Belsham
	  

		By:	simon Belsham	
	 	Its:	CEO	 
	 	 	 	 

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 	HOLDER:	
	  
	  
	  

	 	Nicholas Brown	 
		Print Name Above	
	  
	  
	  
	  

	  
	 /s/ Nicholas brown
	 
	 	Sign Above	 
	  
	  
	  
	  

	  
	 IF Holder is an Entity, specify name and title below:
	  

	  
	 Name:
	 Nicholas Brown
	  

	  
	 Title: 
	 President
	  

 
 
  
 
 
 
 
  
 
 
 
 
 
 
 	 
	36
	

	 

 
 
  
 
 
 
 
  
NOTICE OF EXERCISE
  
 To: The Healing Company Inc.
  
 1. The undersigned hereby elects to purchase shares of Common Stock (the “Common Stock”) of The Healing Company Inc., a Nevada corporation (the “Company”), pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price pursuant to the terms of the Warrant.
  
 2. Please issue certificates representing the shares of Common Stock purchased hereunder in the names and in the denominations indicated below or in an attachment to this notice.
  
 3. Please issue a new Warrant for the unexercised portion of the attached Warrant, if any, in the name of the undersigned.
  
  
 
 
 
 
 
 	Dated: _________________		
	 	 	 	 
	  
	  
	 Print Name Above
	  

	  
	  
	  
	  

	  
	  
	  
	  

	  
	  
	 Sign Above
	  

	  
	  
	  
	  

	  
	  
	 IF Holder is an Entity, specify name and title below:
	  

	  
	  
	  
	  

			Name:                                                                                     	
	  
	  
	Title:____________________________________	 
	 	 	Title	 

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	37
	

	 

 
 
  
 
 
 
 
 NET ISSUANCE ELECTION NOTICE
  
  
 
 
 
 
 
 
 	 To: The Healing Company Inc.  
	  
	 Date:                                         

 
 
  
 
 
  
  
The undersigned hereby elects under Section 2 of the attached Warrant to surrender the right to purchase shares of Common Stock pursuant to the attached Warrant. The Certificate(s) for the shares issuable upon such net issuance election shall be issued in the name of the undersigned or as otherwise indicated below.
  
  
 
 
 
 
 
 
 	  
	  
	  

	  
	  
	 Print Name Above

	  
	  
	  

	  
	  
	  

	  
	  
	  

	  
	  
	 Sign Above

	  
	  
	  

	  
	  
	 IF Holder is an Entity, specify name and title below:

	  
	  
	  

	  
	  
	 Name:                                                                                     

	  
	  
	  

	  
	  
	 Title:____________________________________ 

	  
	  
	  

	  
	  
	  

	 Name for Registration: 
	  
	  

	  
	  
	  

	  
	  
	  

	  
	  
	  

	 Mailing Address:
	  
	  

	  
	  
	  

	  
	  
	  

	  
	  
	  

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	38
	

	 

 
 
  
 
 
 
 
 FORM OF ASSIGNMENT
  
 (To be signed only on transfer of Warrant)
  
 For value received, the undersigned hereby sells, assigns, and transfers unto _ the         right represented by the within Warrant to purchase shares of Common Stock of The Healing Company Inc., a Nevada corporation, to which the within Warrant relates, and appoints attorney                                           to transfer such right on the books of The Healing Company Inc., with full power of substitution in the premises.
  
  
 
 
 
 
 
 	 	 [insert name of Holder]
	
		 	 	 
	 Dated:                          
	By:		
	  
	  
	  
	  

	  
	 Title:
		 
	 	 	[insert address of Holder]	 
	 Signed in the presence of:
	 	 	 

 
 
  
 
 
 
 
  
 
 
 
 
 
 	 
	39

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]